51
|
Baroudjian B, Arangalage D, Cuzzubbo S, Hervier B, Lebbé C, Lorillon G, Tazi A, Zalcman G, Bouattour M, Lioté F, Gautier JF, Brosseau S, Lourenco N, Delyon J. Management of immune-related adverse events resulting from immune checkpoint blockade. Expert Rev Anticancer Ther 2019; 19:209-222. [PMID: 30572735 DOI: 10.1080/14737140.2019.1562342] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
INTRODUCTION Immune checkpoint inhibitors (ICI) are now a standard of care in the treatment of many cancers leading to durable responses in patients with metastatic disease. These agents are generally well tolerated but may lead to the occurrence of immune-related adverse events (irAEs). As any organ may be affected, clinicians should be aware of the broad range of clinical manifestations and symptoms and keep in mind that toxicities may occur late, at any point along a patient's treatment course. Although the most common irAEs are rarely severe, some of them may be associated with great morbidity and even become life-threatening. The rate of occurrence, type and severity of irAEs may vary with the type of ICI; thus, grade 3 and 4 irAEs are reported in more than 55% of patients treated with the combination of ipilimumab 3 mg/kg and nivolumab 1 mg/kg. Area covered: This review presents the management of irAEs resulting from checkpoint blockade, with a focus on rare irAEs. Expert commentary: With the development of immuno-oncology and the expanding role of ICI, physicians have learnt to diagnose and treat most of the irAEs that can occur. This review provides an overview of current guidelines, previously published studies and our multidisciplinary team based practices.
Collapse
Affiliation(s)
| | - Dimitri Arangalage
- b Université Paris 7 Diderot, Sorbonne , Paris , France.,c Department of Cardiology, INSERM U1148 , Bichat Hospital , Paris , France
| | - Stefania Cuzzubbo
- b Université Paris 7 Diderot, Sorbonne , Paris , France.,d Neurology Department , Saint-Louis Hospital , Paris , France
| | - Baptiste Hervier
- e Internal Medecine and immunology Department , Centre National de Référence des Maladies Musculaires, Pitié-Salpêtrière Hospital , Paris , France
| | - Celeste Lebbé
- a Dermatology Department , Saint-Louis Hospital , Paris , France.,b Université Paris 7 Diderot, Sorbonne , Paris , France.,f INSERM U976 , Paris , France
| | - Gwenael Lorillon
- g Pneumology Department , Centre National de Référence de l'Histiocytose Langerhansienne, Saint-Louis Hospital , Paris , France
| | - Abdellatif Tazi
- b Université Paris 7 Diderot, Sorbonne , Paris , France.,h INSERM UMR-1153 (CRESS) , Biostatistics and Clinical Epidemiology Research Team (ECSTRA) , Paris , France
| | - Gerard Zalcman
- b Université Paris 7 Diderot, Sorbonne , Paris , France.,i Thoracic Oncology Department , Bichat-Claude Bernard Hospital , Paris , France
| | - Mohamed Bouattour
- j Digestive Oncology Department , Beaujon Hospital , Clichy , France
| | - Frédéric Lioté
- b Université Paris 7 Diderot, Sorbonne , Paris , France.,k Rheumatology Department, INSERM UMR 1132 , Lariboisière Hospital , Paris , France
| | - Jean-François Gautier
- b Université Paris 7 Diderot, Sorbonne , Paris , France.,l Endocrinology Department , Lariboisière Hospital , Paris , France
| | - Solenn Brosseau
- i Thoracic Oncology Department , Bichat-Claude Bernard Hospital , Paris , France
| | - Nelson Lourenco
- m Gastro-enterology Department , Saint-Louis Hospital , Paris , France
| | - Julie Delyon
- a Dermatology Department , Saint-Louis Hospital , Paris , France.,b Université Paris 7 Diderot, Sorbonne , Paris , France.,f INSERM U976 , Paris , France
| | | |
Collapse
|
52
|
Courty E, Besseiche A, Do TTH, Liboz A, Aguid FM, Quilichini E, Buscato M, Gourdy P, Gautier JF, Riveline JP, Haumaitre C, Buyse M, Fève B, Guillemain G, Blondeau B. Adaptive β-Cell Neogenesis in the Adult Mouse in Response to Glucocorticoid-Induced Insulin Resistance. Diabetes 2019; 68:95-108. [PMID: 30327384 DOI: 10.2337/db17-1314] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/31/2017] [Accepted: 10/11/2018] [Indexed: 11/13/2022]
Abstract
Both type 1 and type 2 diabetes are characterized by deficient insulin secretion and decreased β-cell mass. Thus, regenerative strategies to increase β-cell mass need to be developed. To characterize mechanisms of β-cell plasticity, we studied a model of severe insulin resistance in the adult mouse and defined how β-cells adapt. Chronic corticosterone (CORT) treatment was given to adult mice and led to rapid insulin resistance and adaptive increased insulin secretion. Adaptive and massive increase of β-cell mass was observed during treatment up to 8 weeks. β-Cell mass increase was partially reversible upon treatment cessation and reinduced upon subsequent treatment. β-Cell neogenesis was suggested by an increased number of islets, mainly close to ducts, and increased Sox9 and Ngn3 mRNA levels in islets, but lineage-tracing experiments revealed that neoformed β-cells did not derive from Sox9- or Ngn3-expressing cells. CORT treatment after β-cell depletion partially restored β-cells. Finally, β-cell neogenesis was shown to be indirectly stimulated by CORT because serum from CORT-treated mice increased β-cell differentiation in in vitro cultures of pancreatic buds. Altogether, the results present a novel model of β-cell neogenesis in the adult mouse and identify the presence of neogenic factors in the serum of CORT-treated mice.
Collapse
Affiliation(s)
- Emilie Courty
- Sorbonne Université, INSERM, Saint-Antoine Research Center, Paris, France
- Hospitalo-Universitary Institute, ICAN, Paris, France
| | - Adrien Besseiche
- Sorbonne Université, INSERM, Centre de Recherche des Cordeliers, Paris, France
| | - Thi Thu Huong Do
- Sorbonne Université, INSERM, Saint-Antoine Research Center, Paris, France
- Hospitalo-Universitary Institute, ICAN, Paris, France
| | - Alexandrine Liboz
- Sorbonne Université, INSERM, Saint-Antoine Research Center, Paris, France
- Hospitalo-Universitary Institute, ICAN, Paris, France
| | | | - Evans Quilichini
- Sorbonne Université, CNRS, Institut de Biologie Paris-Seine, Paris, France
| | - Melissa Buscato
- Institute of Metabolic and Cardiovascular Diseases, UMR1048, INSERM, UPS, Université de Toulouse, Toulouse, France
| | - Pierre Gourdy
- Institute of Metabolic and Cardiovascular Diseases, UMR1048, INSERM, UPS, Université de Toulouse, Toulouse, France
- Service de Diabétologie, CHU de Toulouse, Toulouse, France
| | - Jean-François Gautier
- Sorbonne Université, INSERM, Centre de Recherche des Cordeliers, Paris, France
- Lariboisière Hospital, Assistance Publique-Hôpitaux de Paris, Department of Diabetes and Endocrinology, University Paris-Diderot 7, Sorbonne Paris Cité, Paris, France
| | - Jean-Pierre Riveline
- Sorbonne Université, INSERM, Centre de Recherche des Cordeliers, Paris, France
- Lariboisière Hospital, Assistance Publique-Hôpitaux de Paris, Department of Diabetes and Endocrinology, University Paris-Diderot 7, Sorbonne Paris Cité, Paris, France
| | - Cécile Haumaitre
- Sorbonne Université, CNRS, Institut de Biologie Paris-Seine, Paris, France
| | - Marion Buyse
- Sorbonne Université, INSERM, Saint-Antoine Research Center, Paris, France
- Hospitalo-Universitary Institute, ICAN, Paris, France
- Université Paris-Sud, EA 4123, Chatenay-Malabry, France
- Department of Pharmacy, Saint-Antoine Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Bruno Fève
- Sorbonne Université, INSERM, Saint-Antoine Research Center, Paris, France
- Hospitalo-Universitary Institute, ICAN, Paris, France
- Department of Endocrinology, Saint-Antoine Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Ghislaine Guillemain
- Sorbonne Université, INSERM, Saint-Antoine Research Center, Paris, France
- Hospitalo-Universitary Institute, ICAN, Paris, France
| | - Bertrand Blondeau
- Sorbonne Université, INSERM, Saint-Antoine Research Center, Paris, France
- Hospitalo-Universitary Institute, ICAN, Paris, France
| |
Collapse
|
53
|
Julla JB, Ballaire R, Ejlalmanesh T, Gautier JF, Venteclef N, Alzaid F. Isolation and Analysis of Human Monocytes and Adipose Tissue Macrophages. Methods Mol Biol 2019; 1951:33-48. [PMID: 30825142 DOI: 10.1007/978-1-4939-9130-3_3] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Monocytes and macrophages are cells of the innate immune system, existing in circulation and permeating every tissue of the human body. These cells represent the first responders to stress, and their inflammatory activation forms part of virtually every human disease. It is for these reasons that several approaches have been developed in order to phenotypically and functionally analyze these cells and their subpopulations. These inflammatory cells have been consistently demonstrated to undergo inflammatory polarization through the engagement of lipid-activated nuclear receptors, namely, through PPARs and LXRs, which regulate both lipid metabolism and inflammation. Quantitative and phenotypic analyses of monocytes and macrophages are largely dependent on cytometric tools and antibody-based labelling of membrane markers, while functional analyses apply a range of in vitro approaches coupled with secondary analyses of gene or cytokine expression. An important aspect of phenotypic and functional analyses is the purification, enrichment, or appropriate differentiation of biological materials, ensuring experimentation is carried out on monocytes and/or macrophages and not on other cell types occupying the same physical niches. This chapter will focus on the most common analytical approaches applied to the mononuclear phagocytic system, namely, circulating monocytes and adipose tissue macrophages.
Collapse
Affiliation(s)
- Jean-Baptiste Julla
- Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, USPC, Université Paris Descartes, Université Paris Diderot, Paris, France.,Department of Diabetes, Clinical Investigation Centre (CIC-9504), Assistance Publique-Hôpitaux de Paris, Lariboisière Hospital, Paris, France
| | - Raphaelle Ballaire
- Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, USPC, Université Paris Descartes, Université Paris Diderot, Paris, France.,Inovarion, Paris, France
| | - Tina Ejlalmanesh
- Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, USPC, Université Paris Descartes, Université Paris Diderot, Paris, France
| | - Jean-François Gautier
- Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, USPC, Université Paris Descartes, Université Paris Diderot, Paris, France.,Department of Diabetes, Clinical Investigation Centre (CIC-9504), Assistance Publique-Hôpitaux de Paris, Lariboisière Hospital, Paris, France
| | - Nicolas Venteclef
- Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, USPC, Université Paris Descartes, Université Paris Diderot, Paris, France
| | - Fawaz Alzaid
- Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, USPC, Université Paris Descartes, Université Paris Diderot, Paris, France.
| |
Collapse
|
54
|
Choukem SP, Efie DT, Djiogue S, Kaze FF, Mboue-Djieka Y, Boudjeko T, Dongo E, Gautier JF, Kengne AP. Effects of hydroquinone-containing creams on capillary glycemia before and after serial hand washings in Africans. PLoS One 2018; 13:e0202271. [PMID: 30153255 PMCID: PMC6112636 DOI: 10.1371/journal.pone.0202271] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2017] [Accepted: 07/31/2018] [Indexed: 12/02/2022] Open
Abstract
Background Hydroquinone-containing creams cause false increases in capillary glycemia. However, the magnitude of this false increase, and the means to reverse it have not been investigated. Objective To evaluate the technical and clinical impact of hydroquinone-containing creams on capillary glycemia and investigate the efficacy of hand washing and other common practices, in reversing cream effects. Methods We included 91 participants in a quasi-experimental study in Buea, Cameroon. After determining the hydroquinone content of a cream, Caro Light, we used two glucometers with different enzymatic systems (Accu-Chek Active and OneTouch Ultra 2) to measure fasting glycemia after: initial hand washing (reference), application of 1 ml of hydroquinone-containing cream, finger swabbing with wet gauze, sanitizer application and a series of three hand washings following cream application. Reference glycemia was compared to those obtained after various interventions. Statistical significance was assessed by paired sample t-test, clinical significance by total error allowable (TEa), and clinical impact by Parke’s error grid analysis. Results The mean differences in capillary glycemia (Intervention—reference) measured by Accu-Chek Active in mg/dl were 28, 27, 38, 16, 4, and -2 after cream application, finger swabbing, sanitizer application, one, two, and three hand washings respectively. Corresponding values for OneTouch Ultra2 were 41, 44, 64, 22, 5 and -5. These differences, except after two and three hand washings were both statistically (p < 0.0001) and clinically significant (TEa). After cream application, Accu-Check had 9.9% of values in Parke’s Zones C-E, while OneTouch had 18.7%. Conclusion Hydroquinone-containing creams cause significant false increase in capillary glycemia irrespective of the enzymatic system of the glucometer used, and can lead to potentially wrong clinical decisions. A minimum of two hand washings is required prior to capillary glucose measurement.
Collapse
Affiliation(s)
- Simeon-Pierre Choukem
- Department of Internal medicine and Paediatrics, Faculty of Health Sciences, University of Buea, Buea, Cameroon
- Health and Human Development (2HD) Research Network, Douala, Cameroon
- Department of Internal Medicine, Douala General Hospital, Douala, Cameroon
- * E-mail:
| | - Derrick Tembi Efie
- Department of Internal medicine and Paediatrics, Faculty of Health Sciences, University of Buea, Buea, Cameroon
- Health and Human Development (2HD) Research Network, Douala, Cameroon
| | - Sefirin Djiogue
- Department of Animal Biology and Physiology, Faculty of Science, University of Yaounde I, Yaounde, Cameroon
| | - François F. Kaze
- Department of Internal Medicine and Subspecialties, Faculty of Medicine and Biomedical Sciences, University of Yaounde I, Yaounde, Cameroon
| | | | - Thadée Boudjeko
- Department of Biochemistry, Faculty of Science, University of Yaounde I, Yaounde, Cameroon
| | - Etienne Dongo
- Department of Organic Chemistry, Faculty of Sciences, Universityof Yaounde I, Yaounde, Cameroon
| | - Jean-François Gautier
- Department of Diabetes, Endocrinology and Nutrition, Assistance Publique - Hôpitaux de Paris, Lariboisière Hospital, University Paris-Diderot Paris-7, Paris, France
| | - Andre-Pascal Kengne
- South African Medical Research Council and University of Cape Town, Cape Town, South Africa
| |
Collapse
|
55
|
Gauci ML, Boudou P, Baroudjian B, Vidal-Trecan T, Da Meda L, Madelaine-Chambrin I, Basset-Seguin N, Bagot M, Pages C, Mourah S, Resche-Rigon M, Pinel S, Sassier M, Rouby F, Eftekhari P, Lebbé C, Gautier JF. Occurrence of type 1 and type 2 diabetes in patients treated with immunotherapy (anti-PD-1 and/or anti-CTLA-4) for metastatic melanoma: a retrospective study. Cancer Immunol Immunother 2018; 67:1197-1208. [PMID: 29808365 PMCID: PMC11028208 DOI: 10.1007/s00262-018-2178-0] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2017] [Accepted: 05/24/2018] [Indexed: 12/13/2022]
Abstract
Anti-PD-1 and anti-CTLA-4 antibodies cause immune-related side effects such as autoimmune type 1 diabetes (T1D). It has also been suggested that by increasing TNF-α, IL-2 and IFN-γ production, anti-PD-1 and/or anti-CTLA-4 treatment could affect pancreatic beta cell function and insulin sensitivity. This study was based on a retrospective observational analysis from 2 July 2014 to 27 June 2016, which evaluated the occurrence of T1D and changes in glycemia and C-reactive protein (CRP) plasma concentrations in patients undergoing anti-PD-1 and/or anti-CTLA-4 treatment for melanoma at the Saint Louis Hospital. All cases of T1D that developed during immunotherapy registered in the French Pharmacovigilance Database (FPVD) were also considered. Among the 132 patients included, 3 cases of T1D occurred. For the remaining subjects, blood glucose was not significantly affected by anti-PD-1 treatment, but CRP levels (mg/l) significantly increased during anti-PD-1 treatment (p = 0.017). However, 1 case of type 2 diabetes (T2D) occurred (associated with a longer therapy duration). Moreover, glycemia of patients pretreated (n = 44) or concomitantly treated (n = 8) with anti-CTLA-4 tended to increase during anti-PD-1 therapy (p = 0.068). From the FPVD, we obtained 14 cases of T1D that occurred during immunotherapy and were primarily characterized by the rapidity and severity of onset. In conclusion, in addition to inducing this rare immune-related diabetes condition, anti-PD-1 treatment appears to increase CRP levels, a potential inflammatory trigger of insulin resistance, but without any short-term impact on blood glucose level.
Collapse
Affiliation(s)
- Marie-Léa Gauci
- AP-HP Dermatology Department, Saint-Louis Hospital, INSERM U976, Université Paris Diderot-Paris VII, Sorbonne Paris Cité, 1, Avenue Claude Vellefaux, 75010, Paris, France.
| | - Philippe Boudou
- AP-HP Hormonology Department, Saint-Louis Hospital, Université Paris Diderot-Paris VII, Sorbonne Paris Cité, Paris, France
| | - Barouyr Baroudjian
- AP-HP Dermatology Department, Saint-Louis Hospital, INSERM U976, Université Paris Diderot-Paris VII, Sorbonne Paris Cité, 1, Avenue Claude Vellefaux, 75010, Paris, France
| | - Tiphaine Vidal-Trecan
- AP-HP Diabetology Department, Lariboisière Hospital, INSERM U1138; Université Paris Diderot-Paris VII, Sorbonne Paris Cité, Paris, France
| | - Laetitia Da Meda
- AP-HP Dermatology Department, Saint-Louis Hospital, INSERM U976, Université Paris Diderot-Paris VII, Sorbonne Paris Cité, 1, Avenue Claude Vellefaux, 75010, Paris, France
| | - Isabelle Madelaine-Chambrin
- AP-HP Pharmacology Department, Saint-Louis Hospital, INSERM U976, Université Paris Diderot-Paris VII, Sorbonne Paris Cité, Paris, France
| | - Nicole Basset-Seguin
- AP-HP Dermatology Department, Saint-Louis Hospital, INSERM U976, Université Paris Diderot-Paris VII, Sorbonne Paris Cité, 1, Avenue Claude Vellefaux, 75010, Paris, France
| | - Martine Bagot
- AP-HP Dermatology Department, Saint-Louis Hospital, INSERM U976, Université Paris Diderot-Paris VII, Sorbonne Paris Cité, 1, Avenue Claude Vellefaux, 75010, Paris, France
| | - Cécile Pages
- AP-HP Dermatology Department, Saint-Louis Hospital, INSERM U976, Université Paris Diderot-Paris VII, Sorbonne Paris Cité, 1, Avenue Claude Vellefaux, 75010, Paris, France
| | - Samia Mourah
- AP-HP Pharmacogenomic Laboratory, Saint-Louis Hospital, INSERM U976, Université Paris Diderot-Paris VII, Sorbonne Paris Cité, Paris, France
| | - Matthieu Resche-Rigon
- AP-HP Statistics Department, Saint-Louis Hospital, Université Paris Diderot-Paris VII, Sorbonne Paris Cité, Paris, France
| | - Sylvine Pinel
- AP-HP Regional Pharmacologilance Center, Fernand Widal Hospital, Université Paris Diderot-Paris VII, Sorbonne Paris Cité, Paris, France
| | - Marion Sassier
- Regional Pharmacovigilance Center of Caen, Caen University Hospital, Caen, France
| | - Franck Rouby
- Department of Clinical Pharmacology, Regional Pharmacovigilance Center of Marseille, Aix-Marseille University, Marseille, France
| | - Pirayeh Eftekhari
- AP-HP Regional Pharmacologilance Center, Fernand Widal Hospital, Université Paris Diderot-Paris VII, Sorbonne Paris Cité, Paris, France
| | - Céleste Lebbé
- AP-HP Dermatology Department, Saint-Louis Hospital, INSERM U976, Université Paris Diderot-Paris VII, Sorbonne Paris Cité, 1, Avenue Claude Vellefaux, 75010, Paris, France
| | - Jean-François Gautier
- AP-HP Diabetology Department, Lariboisière Hospital, INSERM U1138; Université Paris Diderot-Paris VII, Sorbonne Paris Cité, Paris, France
| |
Collapse
|
56
|
Achkouty G, Paven E, Dillinger JG, Sideris G, Manzo Silberman S, Vidal Trecan T, Riveline JP, Gautier JF, Henry P. P4478Severity of retinopathy and coronary artery calcium score in type 1 and type 2 diabetic patients. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.p4478] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- G Achkouty
- AP-HP - Hospital Lariboisiere, Paris, France
| | - E Paven
- AP-HP - Hospital Lariboisiere, Paris, France
| | | | - G Sideris
- AP-HP - Hospital Lariboisiere, Paris, France
| | | | | | | | - J F Gautier
- AP-HP - Hospital Lariboisiere, Paris, France
| | - P Henry
- AP-HP - Hospital Lariboisiere, Paris, France
| |
Collapse
|
57
|
Fabre S, Clerson P, Launay JM, Gautier JF, Vidal-Trecan T, Riveline JP, Platt A, Abrahamsson A, Miner JN, Hughes G, Richette P, Bardin T. Accuracy of the HumaSens plus point-of-care uric acid meter using capillary blood obtained by fingertip puncture. Arthritis Res Ther 2018; 20:78. [PMID: 29720236 PMCID: PMC5932794 DOI: 10.1186/s13075-018-1585-0] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2017] [Accepted: 03/28/2018] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND The uric acid (UA) level in patients with gout is a key factor in disease management and is typically measured in the laboratory using plasma samples obtained after venous puncture. This study aimed to assess the reliability of immediate UA measurement with capillary blood samples obtained by fingertip puncture with the HumaSensplus point-of-care meter. METHODS UA levels were measured using both the HumaSensplus meter in the clinic and the routine plasma UA method in the biochemistry laboratory of 238 consenting diabetic patients. HumaSensplus capillary and routine plasma UA measurements were compared by linear regression, Bland-Altman plots, intraclass correlation coefficient (ICC), and Lin's concordance coefficient. Values outside the dynamic range of the meter, low (LO) or high (HI), were analyzed separately. The best capillary UA thresholds for detecting hyperuricemia were determined by receiver operating characteristic (ROC) curves. The impact of potential confounding factors (demographic and biological parameters/treatments) was assessed. Capillary and routine plasma UA levels were compared to reference plasma UA measurements by liquid chromatography-mass spectrometry (LC-MS) for a subgroup of 67 patients. RESULTS In total, 205 patients had capillary and routine plasma UA measurements available. ICC was 0.90 (95% confidence interval (CI) 0.87-0.92), Lin's coefficient was 0.91 (0.88-0.93), and the Bland-Altman plot showed good agreement over all tested values. Overall, 17 patients showed values outside the dynamic range. LO values were concordant with plasma values, but HI values were considered uninterpretable. Capillary UA thresholds of 299 and 340 μmol/l gave the best results for detecting hyperuricemia (corresponding to routine plasma UA thresholds of 300 and 360 μmol/l, respectively). No significant confounding factor was found among those tested, except for hematocrit; however, this had a negligible influence on the assay reliability. When capillary and routine plasma results were discordant, comparison with LC-MS measurements showed that plasma measurements had better concordance: capillary UA, ICC 0.84 (95% CI 0.75-0.90), Lin's coefficient 0.84 (0.77-0.91); plasma UA, ICC 0.96 (0.94-0.98), Lin's coefficient 0.96 (0.94-0.98). CONCLUSIONS UA measurements with the HumaSensplus meter were reasonably comparable with those of the laboratory assay. The meter is easy to use and may be useful in the clinic and in epidemiologic studies.
Collapse
Affiliation(s)
- Stéphanie Fabre
- Inserm U1132, Rheumatology Department, Lariboisière Hospital, Paris Diderot University, 2 rue Ambroise Paré, 75010 Paris, France
| | | | - Jean-Marie Launay
- Inserm U942, Biochemistry and Molecular Biology Department, Lariboisière Hospital, Paris Diderot University, Paris, France
| | | | | | | | - Adam Platt
- Precision Medicine and Genomics, IMED Biotech Unit, AstraZeneca, Cambridge, UK
| | - Anna Abrahamsson
- Precision Medicine and Genomics, IMED Biotech Unit, AstraZeneca, Cambridge, UK
| | | | - Glen Hughes
- Precision Medicine and Genomics, IMED Biotech Unit, AstraZeneca, Cambridge, UK
| | - Pascal Richette
- Inserm U1132, Rheumatology Department, Lariboisière Hospital, Paris Diderot University, 2 rue Ambroise Paré, 75010 Paris, France
| | - Thomas Bardin
- Inserm U1132, Rheumatology Department, Lariboisière Hospital, Paris Diderot University, 2 rue Ambroise Paré, 75010 Paris, France
| |
Collapse
|
58
|
Bumbu A, Moutairou A, Matar O, Fumeron F, Velho G, Riveline JP, Gautier JF, Marre M, Roussel R, Potier L. Non-severe hypoglycaemia is associated with weight gain in patients with type 1 diabetes: Results from the Diabetes Control and Complication Trial. Diabetes Obes Metab 2018; 20:1289-1292. [PMID: 29272063 DOI: 10.1111/dom.13197] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/02/2017] [Revised: 12/07/2017] [Accepted: 12/18/2017] [Indexed: 11/28/2022]
Abstract
It is unclear whether the frequent non-severe episodes of hypoglycaemia observed during intensive glucose control in individuals with type 1 diabetes (T1D) are associated with subsequent weight gain. We analysed the association between non-severe hypoglycaemia and weight gain in 1441 Diabetes Control and Complication Trial (DCCT) participants. Non-severe hypoglycaemia was assessed by hypo-score (ie, number of blood glucose values <70 mg/dL divided by the total number of measurements during the DCCT quarterly visits). Significant associations were observed between the hypo-score and annual and total weight gain. The annual weight gain by hypo-score tertiles was 0.8 ± 1.2 (T1), 1.3 ± 1.5 (T2) and 1.4 ± 1.3 kg/y (T3), P < .001 for T2 and T3 vs T1, and for T3 vs T2. The odds ratio for a weight gain of 1.8 kg/y was 2.14 (95% CI, 1.56-2.93) for T2, and 2.53 (95%CI, 1.85-3.45) for T3 vs T1. These differences in weight gain and in risk of weight gain remained significant after adjustment for sex, age, duration of diabetes, HbA1c at baseline and treatment arms. In conclusion, our analysis shows a significant association between non-severe hypoglycaemia and weight gain in individuals with T1D from the DCCT.
Collapse
Affiliation(s)
- Anisoara Bumbu
- Department of Diabetology, Endocrinology and Nutrition, DHU FIRE, Bichat Hospital, AP-HP, Paris, France
| | - Abdul Moutairou
- Université Paris Diderot, Sorbonne Paris Cité, Paris, France
- INSERM U1138, Centre de Recherche des Cordeliers, Paris, France
| | - Odette Matar
- Department of Diabetology, Endocrinology and Nutrition, DHU FIRE, Bichat Hospital, AP-HP, Paris, France
| | - Frédéric Fumeron
- Université Paris Diderot, Sorbonne Paris Cité, Paris, France
- INSERM U1138, Centre de Recherche des Cordeliers, Paris, France
| | - Gilberto Velho
- Université Paris Diderot, Sorbonne Paris Cité, Paris, France
- INSERM U1138, Centre de Recherche des Cordeliers, Paris, France
| | - Jean-Pierre Riveline
- Université Paris Diderot, Sorbonne Paris Cité, Paris, France
- INSERM U1138, Centre de Recherche des Cordeliers, Paris, France
- Department of Diabetes and Endocrinology, DHU FIRE, Lariboisière Hospital, Paris, France
| | - Jean-François Gautier
- Université Paris Diderot, Sorbonne Paris Cité, Paris, France
- INSERM U1138, Centre de Recherche des Cordeliers, Paris, France
- Department of Diabetes and Endocrinology, DHU FIRE, Lariboisière Hospital, Paris, France
| | - Michel Marre
- Department of Diabetology, Endocrinology and Nutrition, DHU FIRE, Bichat Hospital, AP-HP, Paris, France
- Université Paris Diderot, Sorbonne Paris Cité, Paris, France
- INSERM U1138, Centre de Recherche des Cordeliers, Paris, France
| | - Ronan Roussel
- Department of Diabetology, Endocrinology and Nutrition, DHU FIRE, Bichat Hospital, AP-HP, Paris, France
- Université Paris Diderot, Sorbonne Paris Cité, Paris, France
- INSERM U1138, Centre de Recherche des Cordeliers, Paris, France
| | - Louis Potier
- Department of Diabetology, Endocrinology and Nutrition, DHU FIRE, Bichat Hospital, AP-HP, Paris, France
- Université Paris Diderot, Sorbonne Paris Cité, Paris, France
- INSERM U1138, Centre de Recherche des Cordeliers, Paris, France
| |
Collapse
|
59
|
Gautier JF, Fetita LS, Riveline JP, Ibrahim F, Porcher R, Abi Khalil C, Velho G, Choukem SP, Hadjadj S, Larger E, Roussel R, Boudou P, Marre M, Ravussin E, Mauvais-Jarvis F. Sex Difference In the Effect of Fetal Exposure to Maternal Diabetes on Insulin Secretion. J Endocr Soc 2018; 2:391-397. [PMID: 29687090 PMCID: PMC5905383 DOI: 10.1210/js.2017-00482] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/29/2017] [Accepted: 03/19/2018] [Indexed: 01/26/2023] Open
Abstract
We previously showed that fetal exposure to maternal type 1 diabetes (T1D) is associated with altered glucose-stimulated insulin secretion in adult offspring. Here, we investigated whether this β-cell defect displays a sex dimorphism. Twenty-nine adult nondiabetic offspring of T1D mothers (ODMs) were compared with 29 nondiabetic offspring of T1D fathers. We measured early insulin secretion in response to oral glucose and insulin secretion rate in response to intravenous glucose ramping. Insulin sensitivity and body composition were assessed by a euglycemic, hyperinsulinemic clamp and dual-energy X-ray absorptiometry, respectively. In response to oral glucose, male and female ODMs displayed a reduced insulin secretion. In contrast, in response to graded intravenous glucose infusion, only female ODMs (not males) exhibited decreased insulin secretion. There was no defect in response to combined intravenous arginine and glucose, suggesting that male and female ODMs exhibit a functional β-cell defect rather than a reduced β-cell mass. In conclusion, fetal exposure to maternal diabetes predisposes to β-cell dysfunction in adult male and female offspring. This β-cell defect is characterized by a sexual dimorphism following intravenous glucose stimulation.
Collapse
Affiliation(s)
- Jean-François Gautier
- Department of Diabetes and Endocrinology, Assistance Publique - Hôpitaux de Paris (AP-HP), DHU FIRE, Lariboisière Hospital, University Paris-Diderot Paris-7, Paris, France
- Clinical Investigation Center, INSERM-CIC9504, Saint-Louis University Hospital, AP-HP, University Paris-Diderot Paris-7, Paris, France
- INSERM UMRS 1138, Cordeliers Research Center, Paris, France
| | - Lila Sabrina Fetita
- Department of Diabetes and Endocrinology, Assistance Publique - Hôpitaux de Paris (AP-HP), DHU FIRE, Lariboisière Hospital, University Paris-Diderot Paris-7, Paris, France
| | - Jean-Pierre Riveline
- Department of Diabetes and Endocrinology, Assistance Publique - Hôpitaux de Paris (AP-HP), DHU FIRE, Lariboisière Hospital, University Paris-Diderot Paris-7, Paris, France
- INSERM UMRS 1138, Cordeliers Research Center, Paris, France
| | - Fidaa Ibrahim
- Unit of Hormonology, Department of Biochemistry, Saint-Louis University Hospital, AP-HP, Paris, France
| | - Raphaël Porcher
- Department of Biostatistics and Medical Computing, Saint-Louis University Hospital, AP-HP, University Paris-Diderot Paris-7, Paris, France
| | - Charbel Abi Khalil
- Department of Diabetes, Groupe Hospitalier Bichat - Claude Bernard, AP-HP, DHU FIRE, University Paris-Diderot Paris-7, Paris, France
| | - Gilberto Velho
- INSERM UMRS 1138, Cordeliers Research Center, Paris, France
| | - Simeon-Pierre Choukem
- Department of Diabetes and Endocrinology, Assistance Publique - Hôpitaux de Paris (AP-HP), DHU FIRE, Lariboisière Hospital, University Paris-Diderot Paris-7, Paris, France
| | - Samy Hadjadj
- CHU Poitiers, Department of Endocrinology and Diabetes, Poitiers, France
- INSERM CIC 1402, Poitiers, France
| | - Etienne Larger
- Department of Diabetes, Cochin Hospital, AP-HP, Paris, France
| | - Ronan Roussel
- INSERM UMRS 1138, Cordeliers Research Center, Paris, France
- Clinical Investigation Center, Groupe Hospitalier Bichat - Claude Bernard, AP-HP, University Paris-Diderot Paris-7, Paris, France
| | - Philippe Boudou
- Unit of Hormonology, Department of Biochemistry, Saint-Louis University Hospital, AP-HP, Paris, France
| | - Michel Marre
- INSERM UMRS 1138, Cordeliers Research Center, Paris, France
- Department of Diabetes, Groupe Hospitalier Bichat - Claude Bernard, AP-HP, DHU FIRE, University Paris-Diderot Paris-7, Paris, France
- CHU Poitiers, Department of Endocrinology and Diabetes, Poitiers, France
| | - Eric Ravussin
- Penington Biomedical Research Center, Baton Rouge, Louisiana
| | - Franck Mauvais-Jarvis
- Section of Endocrinology, Department of Medicine, Tulane University Health Sciences Center, New Orleans, Louisiana
| |
Collapse
|
60
|
Szpigel A, Hainault I, Carlier A, Venteclef N, Batto AF, Hajduch E, Bernard C, Ktorza A, Gautier JF, Ferré P, Bourron O, Foufelle F. Lipid environment induces ER stress, TXNIP expression and inflammation in immune cells of individuals with type 2 diabetes. Diabetologia 2018; 61:399-412. [PMID: 28988346 DOI: 10.1007/s00125-017-4462-5] [Citation(s) in RCA: 94] [Impact Index Per Article: 15.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/20/2017] [Accepted: 08/24/2017] [Indexed: 02/04/2023]
Abstract
AIMS/HYPOTHESIS Obesity and type 2 diabetes are concomitant with low-grade inflammation affecting insulin sensitivity and insulin secretion. Recently, the thioredoxin interacting protein (TXNIP) has been implicated in the activation process of the NOD-like receptor family, pyrin domain containing 3 (NLRP3) inflammasome. In this study, we aim to determine whether the expression of TXNIP is altered in the circulating immune cells of individuals with type 2 vs type 1 diabetes and whether this can be related to specific causes and consequences of inflammation. METHODS The expression of TXNIP, inflammatory markers, markers of the unfolded protein response (UPR) to endoplasmic reticulum (ER) stress and enzymes involved in sphingolipid metabolism was quantified by quantitative reverse transcription real-time PCR (qRT-PCR) in peripheral blood mononuclear cells (PBMCs) of 13 non-diabetic individuals, 23 individuals with type 1 diabetes and 81 with type 2 diabetes. A lipidomic analysis on the plasma of 13 non-diabetic individuals, 35 individuals with type 1 diabetes and 94 with type 2 diabetes was performed. The effects of ER stress or of specific lipids on TXNIP and inflammatory marker expression were analysed in human monocyte-derived macrophages (HMDMs) and THP-1 cells. RESULTS The expression of TXNIP and inflammatory and UPR markers was increased in the PBMCs of individuals with type 2 diabetes when compared with non-diabetic individuals or individuals with type 1 diabetes. TXNIP expression was significantly correlated with plasma fasting glucose, plasma triacylglycerol concentrations and specific UPR markers. Induction of ER stress in THP-1 cells or cultured HMDMs led to increased expression of UPR markers, TXNIP, NLRP3 and IL-1β. Conversely, a chemical chaperone reduced the expression of UPR markers and TXNIP in PBMCs of individuals with type 2 diabetes. The lipidomic plasma analysis revealed an increased concentration of saturated dihydroceramide and sphingomyelin in individuals with type 2 diabetes when compared with non-diabetic individuals and individuals with type 1 diabetes. In addition, the expression of specific enzymes of sphingolipid metabolism, dihydroceramide desaturase 1 and sphingomyelin synthase 1, was increased in the PBMCs of individuals with type 2 diabetes. Palmitate or C2 ceramide induced ER stress in macrophages as well as increased expression of TXNIP, NLRP3 and IL-1β. CONCLUSIONS/INTERPRETATION In individuals with type 2 diabetes, circulating immune cells display an inflammatory phenotype that can be linked to ER stress and TXNIP expression. Immune cell ER stress can in turn be linked to the specific exogenous and endogenous lipid environment found in type 2 diabetes.
Collapse
Affiliation(s)
- Anaïs Szpigel
- Inserm, UMRS 1138, Sorbonne Universités, UPMC Univ Paris 06; Sorbonne Paris Cité, Université Paris Descartes, Université Paris Diderot; Centre de Recherche des Cordeliers, 15 rue de l'école de médicine, 75006, Paris, France
- Institut de Recherches Servier, Suresnes, France
| | - Isabelle Hainault
- Inserm, UMRS 1138, Sorbonne Universités, UPMC Univ Paris 06; Sorbonne Paris Cité, Université Paris Descartes, Université Paris Diderot; Centre de Recherche des Cordeliers, 15 rue de l'école de médicine, 75006, Paris, France
| | - Aurélie Carlier
- Department of Endocrinology, Nutrition, and Diabetes, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Nicolas Venteclef
- Inserm, UMRS 1138, Sorbonne Universités, UPMC Univ Paris 06; Sorbonne Paris Cité, Université Paris Descartes, Université Paris Diderot; Centre de Recherche des Cordeliers, 15 rue de l'école de médicine, 75006, Paris, France
| | - Anne-Françoise Batto
- Inserm, UMRS 1138, Sorbonne Universités, UPMC Univ Paris 06; Sorbonne Paris Cité, Université Paris Descartes, Université Paris Diderot; Centre de Recherche des Cordeliers, 15 rue de l'école de médicine, 75006, Paris, France
| | - Eric Hajduch
- Inserm, UMRS 1138, Sorbonne Universités, UPMC Univ Paris 06; Sorbonne Paris Cité, Université Paris Descartes, Université Paris Diderot; Centre de Recherche des Cordeliers, 15 rue de l'école de médicine, 75006, Paris, France
| | | | - Alain Ktorza
- Institut de Recherches Servier, Suresnes, France
| | - Jean-François Gautier
- Inserm, UMRS 1138, Sorbonne Universités, UPMC Univ Paris 06; Sorbonne Paris Cité, Université Paris Descartes, Université Paris Diderot; Centre de Recherche des Cordeliers, 15 rue de l'école de médicine, 75006, Paris, France
- Department of Diabetes and Endocrinology, Lariboisière Hospital, DHU FIRE, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Pascal Ferré
- Inserm, UMRS 1138, Sorbonne Universités, UPMC Univ Paris 06; Sorbonne Paris Cité, Université Paris Descartes, Université Paris Diderot; Centre de Recherche des Cordeliers, 15 rue de l'école de médicine, 75006, Paris, France
- Department of Oncology and Endocrine Biochemistry, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Olivier Bourron
- Inserm, UMRS 1138, Sorbonne Universités, UPMC Univ Paris 06; Sorbonne Paris Cité, Université Paris Descartes, Université Paris Diderot; Centre de Recherche des Cordeliers, 15 rue de l'école de médicine, 75006, Paris, France
- Department of Endocrinology, Nutrition, and Diabetes, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Fabienne Foufelle
- Inserm, UMRS 1138, Sorbonne Universités, UPMC Univ Paris 06; Sorbonne Paris Cité, Université Paris Descartes, Université Paris Diderot; Centre de Recherche des Cordeliers, 15 rue de l'école de médicine, 75006, Paris, France.
| |
Collapse
|
61
|
Bouché C, Zucchello A, Troude P, Sarron T, Dumurgier J, Gautier JF. Patients with diabetes and foot ulcer present cognitive dysfunction and express fewer needs in terms of educational support. Diabetes Metab 2018; 45:491-493. [PMID: 29305111 DOI: 10.1016/j.diabet.2017.12.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/29/2017] [Revised: 12/07/2017] [Accepted: 12/10/2017] [Indexed: 10/18/2022]
Affiliation(s)
- C Bouché
- Diabetes and endocrinology, groupe hospitalier Lariboisière-Fernand-Widal, 2, rue Ambroise-Paré, 75010 Paris, France.
| | - A Zucchello
- Diabetes and endocrinology, groupe hospitalier Lariboisière-Fernand-Widal, 2, rue Ambroise-Paré, 75010 Paris, France
| | - P Troude
- Public health department, groupe hospitalier Lariboisière-Fernand-Widal, Paris, France
| | - T Sarron
- Diabetes and endocrinology, groupe hospitalier Lariboisière-Fernand-Widal, 2, rue Ambroise-Paré, 75010 Paris, France
| | - J Dumurgier
- Memory research centre Paris-Nord-Ile-de-France, groupe hospitalier Lariboisiere-Fernand-Widal, Paris, France
| | - J F Gautier
- Diabetes and endocrinology, groupe hospitalier Lariboisière-Fernand-Widal, 2, rue Ambroise-Paré, 75010 Paris, France; Inserm, UMRS 1138, centre de recherche des Cordeliers, Paris, France
| |
Collapse
|
62
|
Gauci ML, Laly P, Vidal-Trecan T, Baroudjian B, Gottlieb J, Madjlessi-Ezra N, Da Meda L, Madelaine-Chambrin I, Bagot M, Basset-Seguin N, Pages C, Mourah S, Boudou P, Lebbé C, Gautier JF. Autoimmune diabetes induced by PD-1 inhibitor-retrospective analysis and pathogenesis: a case report and literature review. Cancer Immunol Immunother 2017; 66:1399-1410. [PMID: 28634815 PMCID: PMC11028556 DOI: 10.1007/s00262-017-2033-8] [Citation(s) in RCA: 93] [Impact Index Per Article: 13.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2017] [Accepted: 06/12/2017] [Indexed: 12/16/2022]
Abstract
Anti-PD-1 antibody treatment is approved in advanced melanoma and provides median overall survival over 24 months. The main treatment-related side effects are immune-related adverse events, which include rash, pruritus, vitiligo, thyroiditis, diarrhoea, hepatitis and pneumonitis. We report a case of autoimmune diabetes related to nivolumab treatment. A 73-year-old man was treated in second line with nivolumab at 3 mg/kg every two weeks for metastatic melanoma. At 6 weeks of treatment, he displayed diabetic ketoacidosis. Nivolumab was withheld 3.5 weeks and insulin therapy was initiated, enabling a normalization of glycaemia and the disappearance of symptoms. Laboratory investigations demonstrated the presence of islet cell autoantibodies, while C-peptide was undetectable. Retrospective explorations on serum banked at week 0 and 3 months before the start of nivolumab, already showed the presence of autoantibodies, but normal insulin, C-peptide secretion and glycaemia. Partial response was obtained at month 3, and nivolumab was then resumed at the same dose. The clinical context and biological investigations before, at and after nivolumab initiation suggest the autoimmune origin of this diabetes, most likely induced by anti-PD-1 antibody in a predisposed patient. The role of PD-1/PD-L1 binding is well known in the pathogenesis of type 1 diabetes. Therefore, this rare side effect can be expected in a context of anti-PD-1 treatment. Glycaemia should be monitored during PD-1/PD-L1 blockade. The presence of autoantibodies before treatment could identify individuals at risk of developing diabetes, but systematic titration may not be relevant considering the rarity of this side effect.
Collapse
Affiliation(s)
- Marie-Léa Gauci
- AP-HP Dermatology Department, Saint-Louis Hospital, 1 avenue Claude Vellefaux, 75475, Paris Cedex 10, France.
- INSERM U976, Université Paris Diderot-Paris VII, Sorbonne Paris Cité, Paris, France.
| | - Pauline Laly
- AP-HP Dermatology Department, Saint-Louis Hospital, 1 avenue Claude Vellefaux, 75475, Paris Cedex 10, France
- INSERM U976, Université Paris Diderot-Paris VII, Sorbonne Paris Cité, Paris, France
| | - Tiphaine Vidal-Trecan
- AP-HP Diabetology Department, Lariboisière Hospital, Paris, France
- INSERM U1138, Université Paris Diderot-Paris VII, Sorbonne Paris Cité, Paris, France
| | - Barouyr Baroudjian
- AP-HP Dermatology Department, Saint-Louis Hospital, 1 avenue Claude Vellefaux, 75475, Paris Cedex 10, France
- INSERM U976, Université Paris Diderot-Paris VII, Sorbonne Paris Cité, Paris, France
| | - Jérémy Gottlieb
- AP-HP Dermatology Department, Saint-Louis Hospital, 1 avenue Claude Vellefaux, 75475, Paris Cedex 10, France
- INSERM U976, Université Paris Diderot-Paris VII, Sorbonne Paris Cité, Paris, France
| | - Nika Madjlessi-Ezra
- AP-HP Dermatology Department, Saint-Louis Hospital, 1 avenue Claude Vellefaux, 75475, Paris Cedex 10, France
- INSERM U976, Université Paris Diderot-Paris VII, Sorbonne Paris Cité, Paris, France
| | - Laetitia Da Meda
- AP-HP Dermatology Department, Saint-Louis Hospital, 1 avenue Claude Vellefaux, 75475, Paris Cedex 10, France
- INSERM U976, Université Paris Diderot-Paris VII, Sorbonne Paris Cité, Paris, France
| | - Isabelle Madelaine-Chambrin
- INSERM U976, Université Paris Diderot-Paris VII, Sorbonne Paris Cité, Paris, France
- AP-HP Pharmacology Department, Saint-Louis Hospital, Paris, France
| | - Martine Bagot
- AP-HP Dermatology Department, Saint-Louis Hospital, 1 avenue Claude Vellefaux, 75475, Paris Cedex 10, France
- INSERM U976, Université Paris Diderot-Paris VII, Sorbonne Paris Cité, Paris, France
| | - Nicole Basset-Seguin
- AP-HP Dermatology Department, Saint-Louis Hospital, 1 avenue Claude Vellefaux, 75475, Paris Cedex 10, France
- INSERM U976, Université Paris Diderot-Paris VII, Sorbonne Paris Cité, Paris, France
| | - Cécile Pages
- AP-HP Dermatology Department, Saint-Louis Hospital, 1 avenue Claude Vellefaux, 75475, Paris Cedex 10, France
- INSERM U976, Université Paris Diderot-Paris VII, Sorbonne Paris Cité, Paris, France
| | - Samia Mourah
- INSERM U976, Université Paris Diderot-Paris VII, Sorbonne Paris Cité, Paris, France
- AP-HP Pharmacogenomic Laboratory, Saint-Louis Hospital, Paris, France
| | - Philippe Boudou
- AP-HP Hormonology Department, Saint-Louis Hospital, Paris, France
- Université Paris Diderot-Paris VII, Sorbonne Paris Cité, Paris, France
| | - Céleste Lebbé
- AP-HP Dermatology Department, Saint-Louis Hospital, 1 avenue Claude Vellefaux, 75475, Paris Cedex 10, France
- INSERM U976, Université Paris Diderot-Paris VII, Sorbonne Paris Cité, Paris, France
| | - Jean-François Gautier
- AP-HP Diabetology Department, Lariboisière Hospital, Paris, France
- INSERM U1138, Université Paris Diderot-Paris VII, Sorbonne Paris Cité, Paris, France
| |
Collapse
|
63
|
Ayina CNA, Endomba FTA, Mandengue SH, Noubiap JJN, Ngoa LSE, Boudou P, Gautier JF, Mbanya JC, Sobngwi E. Association of the leptin-to-adiponectin ratio with metabolic syndrome in a sub-Saharan African population. Diabetol Metab Syndr 2017; 9:66. [PMID: 28878827 PMCID: PMC5584041 DOI: 10.1186/s13098-017-0265-6] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/06/2017] [Accepted: 08/29/2017] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND Worldwide there is an increased prevalence of metabolic syndrome mainly due to life-style modifications, and Africans are not saved of this situation. Many markers have been studied to predict the risk of this syndrome but the most used are leptin and adiponectin. Data on these metabolic markers are scare in Africa and this study aimed to assess the association between the leptin-to-adiponectin ratio (LAR) with metabolic syndrome in a Cameroonian population. METHODS This was a cross-sectional study that included 476 adults among a general population of Cameroon. Data collected concerned the body mass index, waist circumference, systolic blood pressure, diastolic blood pressure, fasting blood glucose, plasma lipids, adiponectin, leptin, insulin and homeostasis model for assessment of insulin resistance (HOMA-IR). To assess correlations we used Spearman's analyses and association of the studied variables with metabolic syndrome were done using binary logistic regression analysis. RESULTS The leptin to adiponectin ratio was significantly and positively correlated with the body mass index (r = 0.669, p < 0.0001), waist circumference (r = 0.595, p < 0.0001), triglycerides (r = 0.190, p = 0.001), insulin levels (r = 0.333, p < 0.0001) and HOMA-IR (r = 0.306, p < 0.0001). Binary logistic regression analysis revealed that leptin, adiponectin and LAR were significantly associated with metabolic syndrome with respective unadjusted OR of 1.429, 0.468 and 1.502. After adjustment, for age and sex, the associations remained significative; LAR was also found to be significantly associated with metabolic syndrome (OR = 1.573, p value =0.000) as well as lower levels of adiponectin (OR = 0.359, p value =0.000) and higher levels of leptin (OR = 1.469, p value =0.001). CONCLUSION This study revealed that LAR is significantly associated with metabolic syndrome in sub-Saharan African population, independently to age and sex.
Collapse
Affiliation(s)
- Clarisse Noël A. Ayina
- Department of Animal Science, Faculty of Science, University of Douala, Douala, Cameroon
| | - Francky Teddy A. Endomba
- Department of Internal Medicine and Specialties, Faculty of Medicine and Biomedical Science, University of Yaoundé I, Yaoundé, Cameroon
| | | | - Jean Jacques N. Noubiap
- Department of Medicine, Groote Schuur Hospital, University of Cape Town, Cape Town, South Africa
| | - Laurent Serge Etoundi Ngoa
- Department of Animal Science, Higher Teacher’s Training College, University of Yaoundé I, Yaounde, Cameroon
| | - Philippe Boudou
- Department of Hormonal Biology, Saint-Louis Hospital, Public Assistance -Paris Hospitals, University Paris-Diderot Paris-7, Paris, France
| | - Jean-François Gautier
- Department of Diabetes and Endocrinology, Lariboisiere Hospital, Public Assistance – Paris Hospitals, University Paris-Diderot Paris-7, Paris, France
- INSERM UMRS 1138, Cordeliers Research Centre, University Pierre et Marie Curie-Paris 6, Paris, France
| | - Jean Claude Mbanya
- Department of Internal Medicine and Specialties, Faculty of Medicine and Biomedical Science, University of Yaoundé I, Yaoundé, Cameroon
- Laboratory for Molecular Medicine and Metabolism, Biotechnology Center, University of Yaoundé I, Yaoundé, Cameroon
- National Obesity Center, Yaoundé Central Hospital, Yaoundé, Cameroon
| | - Eugene Sobngwi
- Department of Internal Medicine and Specialties, Faculty of Medicine and Biomedical Science, University of Yaoundé I, Yaoundé, Cameroon
- Laboratory for Molecular Medicine and Metabolism, Biotechnology Center, University of Yaoundé I, Yaoundé, Cameroon
- National Obesity Center, Yaoundé Central Hospital, Yaoundé, Cameroon
| |
Collapse
|
64
|
Dos Santos RS, Daures M, Philippi A, Romero S, Marselli L, Marchetti P, Senée V, Bacq D, Besse C, Baz B, Marroquí L, Ivanoff S, Masliah-Planchon J, Nicolino M, Soulier J, Socié G, Eizirik DL, Gautier JF, Julier C. dUTPase ( DUT) Is Mutated in a Novel Monogenic Syndrome With Diabetes and Bone Marrow Failure. Diabetes 2017; 66:1086-1096. [PMID: 28073829 DOI: 10.2337/db16-0839] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/10/2016] [Accepted: 01/05/2017] [Indexed: 11/13/2022]
Abstract
We describe a new syndrome characterized by early-onset diabetes associated with bone marrow failure, affecting mostly the erythrocytic lineage. Using whole-exome sequencing in a remotely consanguineous patient from a family with two affected siblings, we identified a single homozygous missense mutation (chr15.hg19:g.48,626,619A>G) located in the dUTPase (DUT) gene (National Center for Biotechnology Information Gene ID 1854), affecting both the mitochondrial (DUT-M p.Y142C) and the nuclear (DUT-N p.Y54C) isoforms. We found the same homozygous mutation in an unrelated consanguineous patient with diabetes and bone marrow aplasia from a family with two affected siblings, whereas none of the >60,000 subjects from the Exome Aggregation Consortium (ExAC) was homozygous for this mutation. This replicated observation probability was highly significant, thus confirming the role of this DUT mutation in this syndrome. DUT is a key enzyme for maintaining DNA integrity by preventing misincorporation of uracil into DNA, which results in DNA toxicity and cell death. We showed that DUT silencing in human and rat pancreatic β-cells results in apoptosis via the intrinsic cell death pathway. Our findings support the importance of tight control of DNA metabolism for β-cell integrity and warrant close metabolic monitoring of patients treated by drugs affecting dUTP balance.
Collapse
Affiliation(s)
| | - Mathilde Daures
- INSERM UMRS 958, Faculté de Médecine Paris Diderot, Université Paris Diderot-Paris 7, Université Sorbonne Paris Cité, Paris, France
| | - Anne Philippi
- INSERM UMRS 958, Faculté de Médecine Paris Diderot, Université Paris Diderot-Paris 7, Université Sorbonne Paris Cité, Paris, France
| | - Sophie Romero
- INSERM UMRS 958, Faculté de Médecine Paris Diderot, Université Paris Diderot-Paris 7, Université Sorbonne Paris Cité, Paris, France
| | - Lorella Marselli
- Department of Clinical and Experimental Medicine, Islet Cell Laboratory, University of Pisa, Pisa, Italy
| | - Piero Marchetti
- Department of Clinical and Experimental Medicine, Islet Cell Laboratory, University of Pisa, Pisa, Italy
| | - Valérie Senée
- INSERM UMRS 958, Faculté de Médecine Paris Diderot, Université Paris Diderot-Paris 7, Université Sorbonne Paris Cité, Paris, France
| | - Delphine Bacq
- Centre National de Génotypage, Institut de Génomique, Commissariat à l'Energie Atomique, Evry, France
| | - Céline Besse
- Centre National de Génotypage, Institut de Génomique, Commissariat à l'Energie Atomique, Evry, France
| | - Baz Baz
- Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Department of Diabetes and Endocrinology, Université Paris Diderot-Paris 7, Université Sorbonne Paris Cité, Paris, France
| | - Laura Marroquí
- ULB Center for Diabetes Research, Medical Faculty, Université Libre de Bruxelles, Brussels, Belgium
| | - Sarah Ivanoff
- Aplastic Anemia Reference Centre, Hematology Laboratory, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, INSERM U944, Université Paris Diderot-Paris 7, Université Sorbonne Paris Cité, Paris, France
| | - Julien Masliah-Planchon
- Aplastic Anemia Reference Centre, Hematology Laboratory, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, INSERM U944, Université Paris Diderot-Paris 7, Université Sorbonne Paris Cité, Paris, France
| | - Marc Nicolino
- Hôpital Femme-Mère-Enfant, Division of Pediatric Endocrinology, Hospices Civils de Lyon, Université Lyon 1, Lyon, France
| | - Jean Soulier
- Aplastic Anemia Reference Centre, Hematology Laboratory, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, INSERM U944, Université Paris Diderot-Paris 7, Université Sorbonne Paris Cité, Paris, France
| | - Gérard Socié
- Hematology Transplantation, Department of Hematology, Immunology and Oncology, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Decio L Eizirik
- ULB Center for Diabetes Research, Medical Faculty, Université Libre de Bruxelles, Brussels, Belgium
| | - Jean-François Gautier
- Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Department of Diabetes and Endocrinology, Université Paris Diderot-Paris 7, Université Sorbonne Paris Cité, Paris, France
| | - Cécile Julier
- INSERM UMRS 958, Faculté de Médecine Paris Diderot, Université Paris Diderot-Paris 7, Université Sorbonne Paris Cité, Paris, France
| |
Collapse
|
65
|
Lontchi-Yimagou E, Nguewa JL, Assah F, Noubiap JJ, Boudou P, Djahmeni E, Balti EV, Atogho-Tiedeu B, Gautier JF, Mbanya JC, Sobngwi E. Ketosis-prone atypical diabetes in Cameroonian people with hyperglycaemic crisis: frequency, clinical and metabolic phenotypes. Diabet Med 2017; 34:426-431. [PMID: 27657549 DOI: 10.1111/dme.13264] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 09/16/2016] [Indexed: 12/29/2022]
Abstract
AIM It is unclear whether ketosis-prone diabetes is a specific type or a subtype of Type 2 diabetes. We aimed to describe the clinical and metabolic features of ketosis-prone diabetes in a sub-Saharan population. METHODS We consecutively enrolled and characterized 173 people with non-autoimmune diabetes admitted for hyperglycaemic crisis at the Yaoundé Central Hospital, Cameroon. Blood samples were collected for fasting glucose, HbA1c , lipid profile and C-peptide assays with insulin resistance and secretion estimation by homeostasis model assessment. People were classified as having Type 2 diabetes (n = 124) or ketosis-prone diabetes (n = 49). Ketosis-prone diabetes was sub-classified as new-onset ketotic phase (n = 34) or non-ketotic phase (n = 15). RESULTS Ketosis-prone diabetes was found in 28.3% of the hyperglycaemic crises. Age at diabetes diagnosis was comparable in Type 2 and ketosis-prone diabetes [48 ± 14 vs 47 ± 11 years; P = 0.13] with a similar sex distribution. Overall BMI was 27.7 ± 13.4 kg/m2 and was ≥ 25 kg/m2 in 55.8% of those taking part, however, 73.5% of those with ketosis-prone diabetes reported weight loss of > 5% at diagnosis. Blood pressure and lipid profile were comparable in both types. Ketosis-prone diabetes in the ketotic phase was characterized by lower insulin secretion and higher serum triglycerides compared with non-ketotic ketosis prone and Type 2 diabetes. Type 2 and ketosis prone diabetes in the non-ketotic phase were comparable in terms of lipid profile, blood pressure, waist-to-hip ratio, BMI and fat mass, insulin secretion and insulin resistance indices. CONCLUSIONS Ketosis-prone diabetes is likely to be a subtype of Type 2 diabetes with the potential to develop acute insulinopenic episodes.
Collapse
Affiliation(s)
- E Lontchi-Yimagou
- Laboratory for Molecular Medicine and Metabolism, Biotechnology Center, University of Yaoundé I, Yaoundé, Cameroon
| | - J L Nguewa
- INSERM, UMRS 1138, Centre de Recherche des Cordeliers, Paris, France
| | - F Assah
- National Obesity Centre, Yaoundé Central Hospital, Yaoundé, Cameroon
| | - J J Noubiap
- Department of Medicine, Groote Schuur Hospital and University of Cape Town, Cape Town, South Africa
| | - P Boudou
- Saint-Louis University Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France
| | - E Djahmeni
- National Obesity Centre, Yaoundé Central Hospital, Yaoundé, Cameroon
| | - E V Balti
- Diabetes Research Center, Brussels Free University-VUB, Brussels, Belgium
| | - B Atogho-Tiedeu
- Laboratory for Molecular Medicine and Metabolism, Biotechnology Center, University of Yaoundé I, Yaoundé, Cameroon
| | - J F Gautier
- INSERM, UMRS 1138, Centre de Recherche des Cordeliers, Paris, France
- Saint-Louis University Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France
| | - J C Mbanya
- Laboratory for Molecular Medicine and Metabolism, Biotechnology Center, University of Yaoundé I, Yaoundé, Cameroon
- National Obesity Centre, Yaoundé Central Hospital, Yaoundé, Cameroon
- Department of Internal Medicine, University of Yaoundé I, Yaoundé, Cameroon
| | - E Sobngwi
- Laboratory for Molecular Medicine and Metabolism, Biotechnology Center, University of Yaoundé I, Yaoundé, Cameroon
- National Obesity Centre, Yaoundé Central Hospital, Yaoundé, Cameroon
- Department of Internal Medicine, University of Yaoundé I, Yaoundé, Cameroon
| |
Collapse
|
66
|
Choukem SP, Kamdeu-Chedeu J, Leary SD, Mboue-Djieka Y, Nebongo DN, Akazong C, Mapoure YN, Hamilton-Shield JP, Gautier JF, Mbanya JC. Overweight and obesity in children aged 3-13 years in urban Cameroon: a cross-sectional study of prevalence and association with socio-economic status. BMC Obes 2017; 4:7. [PMID: 28163924 PMCID: PMC5286775 DOI: 10.1186/s40608-017-0146-4] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/17/2016] [Accepted: 01/28/2017] [Indexed: 11/29/2022]
Abstract
Background Childhood overweight/obesity is increasing rapidly in developing countries. There is a need to provide more evidence on its burden in sub-Saharan Africa, and to identify associated factors in order to set preventive measures. We aimed to determine the prevalence of overweight/obesity and assess its association with the socioeconomic status in nursery and primary school children in urban Cameroon. Methods In this cross-sectional study, we included by multi-staged cluster random sampling 1343 children from high (HSES, n = 673) and low (LSES, n = 670) socioeconomic status schools in Douala. Parent/child demographic data were collected, and children’s anthropometric parameters were measured using validated methods. The World Health Organization body mass index-for-age reference curves were used. Results The prevalence of overweight/obesity was 12.5% (13.2% in girls, 11.8% in boys). The risk of overweight/obesity was 2.40 (95% CI 1.70, 3.40) higher in HSES children compared to LSES after adjusting for age and gender. However this association was attenuated to 1.18 (95% CI 0.59, 2.35) once adjustment had been made for a range of potential confounders. Conclusions Overweight/obesity is relatively common in sub-Saharan African children and prevalence is associated with HSES. However, this association may be mediated by sweet drink consumption, passive means of travel to school and not doing sport at school. We suggest that these potentially modifiable behaviors may be effective targets for obesity prevention. Further studies should specifically focus on unhealthy behaviors that mediate overweight/obesity as well as other non communicable diseases in children. Electronic supplementary material The online version of this article (doi:10.1186/s40608-017-0146-4) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Simeon-Pierre Choukem
- Health and Human Development (2HD) Research Group, Douala, Cameroon.,Department of Internal Medicine, Douala General Hospital, P.O. Box 4856, Douala, Cameroon.,Department of Internal Medicine and Pediatrics, Faculty of Health Sciences, University of Buea, Buea, Cameroon
| | - Josiane Kamdeu-Chedeu
- Faculty of Medicine and Pharmaceutical Sciences, University of Douala, Douala, Cameroon
| | - Sam D Leary
- Biomedical Research Unit in Nutrition, Diet and Lifestyle, University of Bristol, Bristol, UK
| | | | - Daniel N Nebongo
- Health and Human Development (2HD) Research Group, Douala, Cameroon
| | | | - Yacouba N Mapoure
- Department of Internal Medicine, Douala General Hospital, P.O. Box 4856, Douala, Cameroon.,Faculty of Medicine and Pharmaceutical Sciences, University of Douala, Douala, Cameroon
| | | | - Jean-François Gautier
- Department of Diabetes, Endocrinology and Nutrition, Assistance Publique - Hôpitaux de Paris, Lariboisière Hospital, University Paris-Diderot Paris-7, 2 rue Ambroise Paré, 75010 Paris, France
| | - Jean Claude Mbanya
- National Centre of Obesity, Diabetes and Endocrinology, Yaoundé Central Hospital, Yaoundé, Cameroon.,Laboratory of molecular and metabolic medicine, Biotechnology Center, University of Yaoundé 1, Yaoundé, Cameroon.,Department of Internal Medicine and Subspecialties, Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Yaoundé, Cameroon
| |
Collapse
|
67
|
Balazard F, Le Fur S, Valtat S, Valleron AJ, Bougnères P, Thevenieau D, Chatel CF, Desailloud R, Bony-Trifunovic H, Ducluzeau PH, Coutant R, Caudrelier S, Pambou A, Dubosclard E, Joubert F, Jan P, Marcoux E, Bertrand AM, Mignot B, Penformis A, Stuckens C, Piquemal R, Barat P, Rigalleau V, Stheneur C, Fournier S, Kerlan V, Metz C, Fargeot-Espaliat A, Reznic Y, Olivier F, Gueorguieva I, Monier A, Radet C, Gajdos V, Terral D, Vervel C, Bendifallah D, Signor CB, Dervaux D, Benmahammed A, Loeuille GA, Popelard F, Guillou A, Benhamou PY, Khoury J, Brossier JP, Bassil J, Clavel S, Le Luyer B, Bougnères P, Labay F, Guemas I, Weill J, Cappoen JP, Nadalon S, Lienhardt-Roussie A, Paoli A, Kerouedan C, Yollin E, Nicolino M, Simonin G, Cohen J, Atlan C, Tamboura A, Dubourg H, Pignol ML, Talon P, Jellimann S, Chaillous L, Baron S, Bortoluzzi MN, Baechler E, Salet R, Zelinsky-Gurung A, Dallavale F, Larger E, Laloi-Michelin M, Gautier JF, Guérin B, Oilleau L, Pantalone L, Lukas C, Guilhem I, De Kerdanet M, Wielickzo MC, Priou-Guesdon M, Richard O, Kurtz F, Laisney N, Ancelle D, Parlier G, Boniface C, Bockel DP, Dufillot D, Razafimahefa B, Gourdy P, Lecomte P, Pepin-Donat M, Combes-Moukhovsky ME, Zymmermann B, Raoulx M, Dumont AGEC. Association of environmental markers with childhood type 1 diabetes mellitus revealed by a long questionnaire on early life exposures and lifestyle in a case-control study. BMC Public Health 2016; 16:1021. [PMID: 27682602 PMCID: PMC5041527 DOI: 10.1186/s12889-016-3690-9] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2016] [Accepted: 09/20/2016] [Indexed: 12/22/2022] Open
Abstract
Background The incidence of childhood type 1 diabetes (T1D) incidence is rising in many countries, supposedly because of changing environmental factors, which are yet largely unknown. The purpose of the study was to unravel environmental markers associated with T1D. Methods Cases were children with T1D from the French Isis-Diab cohort. Controls were schoolmates or friends of the patients. Parents were asked to fill a 845-item questionnaire investigating the child’s environment before diagnosis. The analysis took into account the matching between cases and controls. A second analysis used propensity score methods. Results We found a negative association of several lifestyle variables, gastroenteritis episodes, dental hygiene, hazelnut cocoa spread consumption, wasp and bee stings with T1D, consumption of vegetables from a farm and death of a pet by old age. Conclusions The found statistical association of new environmental markers with T1D calls for replication in other cohorts and investigation of new environmental areas. Trial registration Clinical-Trial.gov NCT02212522. Registered August 6, 2014. Electronic supplementary material The online version of this article (doi:10.1186/s12889-016-3690-9) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- F Balazard
- Sorbonne Universités, UPMC Univ Paris 06, CNRS, Paris, France. .,INSERM U1169, Hôpital Bicêtre, Université Paris-Sud, Kremlin-Bicêtre, France.
| | - S Le Fur
- INSERM U1169, Hôpital Bicêtre, Université Paris-Sud, Kremlin-Bicêtre, France.,Department of pediatric endocrinology, Hôpital Bicêtre, Kremlin-Bicêtre, France
| | - S Valtat
- INSERM U1169, Hôpital Bicêtre, Université Paris-Sud, Kremlin-Bicêtre, France
| | - A J Valleron
- INSERM U1169, Hôpital Bicêtre, Université Paris-Sud, Kremlin-Bicêtre, France
| | - P Bougnères
- INSERM U1169, Hôpital Bicêtre, Université Paris-Sud, Kremlin-Bicêtre, France.,Department of pediatric endocrinology, Hôpital Bicêtre, Kremlin-Bicêtre, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
68
|
Gautier JF, Monguillon P, Verier-Mine O, Valensi P, Fiquet B, Dejager S, Charbonnel B. Which oral antidiabetic drug to combine with metformin to minimize the risk of hypoglycemia when initiating basal insulin?: A randomized controlled trial of a DPP4 inhibitor versus insulin secretagogues. Diabetes Res Clin Pract 2016; 116:26-8. [PMID: 27321312 DOI: 10.1016/j.diabres.2016.04.008] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/27/2015] [Revised: 02/12/2016] [Accepted: 04/15/2016] [Indexed: 11/25/2022]
Abstract
We conducted a pilot study to evaluate two therapeutic strategies at the time of insulin initiation in type 2 diabetic patients insufficiently controlled with metformin+insulin-secretagogues (IS, sulfonylureas or glinides). Patients were randomized to remain under the same dual therapy or to receive metformin+DPP4 inhibitors while starting insulin. Similar glycemic control was achieved in both groups. However less hypoglycemia was observed with DPP4 inhibitors despite higher doses of insulin.
Collapse
Affiliation(s)
- J F Gautier
- Diabetes, Endocrinology and Nutrition Department, Lariboisière Hospital, Paris, France
| | | | - O Verier-Mine
- Diabetes, Endocrinology and Nutrition Department, Jean Bernard Hospital, Valenciennes, France
| | - P Valensi
- Endocrinology, Diabetology and Nutrition Department, Jean Verdier Hospital, APHP, Paris Nord University, CRNH-IdF, CINFO, Bondy, France
| | - B Fiquet
- Scientific and Medical Affairs, Novartis Pharma, Rueil Malmaison, France.
| | - S Dejager
- Endocrinology and Metabolism Department, Pitié Salpétrière Hospital, Paris, France
| | - B Charbonnel
- Endocrinology and Metabolism Department, CHU Nantes, France
| |
Collapse
|
69
|
Ebou MH, Singh-Estivalet A, Launay JM, Callebert J, Tronche F, Ferré P, Gautier JF, Guillemain G, Bréant B, Blondeau B, Riveline JP. Correction: Glucocorticoids Inhibit Basal and Hormone-Induced Serotonin Synthesis in Pancreatic Beta Cells. PLoS One 2016; 11:e0155174. [PMID: 27144400 PMCID: PMC4856364 DOI: 10.1371/journal.pone.0155174] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
[This corrects the article DOI: 10.1371/journal.pone.0149343.].
Collapse
|
70
|
Kaiser M, Kretzschmar Y, Kienhöfer J, Gautier JF, Penfornis A, Charpentier G, Martinez L, Eschwège E, Gourdy P. Der Anteil der Patienten, die mit Liraglutid erfolgreich behandelt wurden – Ergebnisse einer Post-hoc-Analyse der EVIDENCE-Studie. DIABETOL STOFFWECHS 2016. [DOI: 10.1055/s-0036-1580966] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
71
|
Hasni Ebou M, Singh-Estivalet A, Launay JM, Callebert J, Tronche F, Ferré P, Gautier JF, Guillemain G, Bréant B, Blondeau B, Riveline JP. Glucocorticoids Inhibit Basal and Hormone-Induced Serotonin Synthesis in Pancreatic Beta Cells. PLoS One 2016; 11:e0149343. [PMID: 26901633 PMCID: PMC4763453 DOI: 10.1371/journal.pone.0149343] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2015] [Accepted: 01/29/2016] [Indexed: 12/31/2022] Open
Abstract
Diabetes is a major complication of chronic Glucocorticoids (GCs) treatment. GCs induce insulin resistance and also inhibit insulin secretion from pancreatic beta cells. Yet, a full understanding of this negative regulation remains to be deciphered. In the present study, we investigated whether GCs could inhibit serotonin synthesis in beta cell since this neurotransmitter has been shown to be involved in the regulation of insulin secretion. To this aim, serotonin synthesis was evaluated in vitro after treatment with GCs of either islets from CD1 mice or MIN6 cells, a beta-cell line. We also explored the effect of GCs on the stimulation of serotonin synthesis by several hormones such as prolactin and GLP 1. We finally studied this regulation in islet in two in vivo models: mice treated with GCs and with liraglutide, a GLP1 analog, and mice deleted for the glucocorticoid receptor in the pancreas. We showed in isolated islets and MIN6 cells that GCs decreased expression and activity of the two key enzymes of serotonin synthesis, Tryptophan Hydroxylase 1 (Tph1) and 2 (Tph2), leading to reduced serotonin contents. GCs also blocked the induction of serotonin synthesis by prolactin or by a previously unknown serotonin activator, the GLP-1 analog exendin-4. In vivo, activation of the Glucagon-like-Peptide-1 receptor with liraglutide during 4 weeks increased islet serotonin contents and GCs treatment prevented this increase. Finally, islets from mice deleted for the GR in the pancreas displayed an increased expression of Tph1 and Tph2 and a strong increased serotonin content per islet. In conclusion, our results demonstrate an original inhibition of serotonin synthesis by GCs, both in basal condition and after stimulation by prolactin or activators of the GLP-1 receptor. This regulation may contribute to the deleterious effects of GCs on beta cells.
Collapse
Affiliation(s)
- Moina Hasni Ebou
- INSERM, UMR_S 1138, Centre de Recherche des Cordeliers, F-75006, Paris, France
- Sorbonne Universités, UPMC, Univ Paris 06, UMR_S 1138, Centre de Recherche des Cordeliers, F-75006, Paris, France
- Université Paris Descartes, Sorbonne Paris Cité, UMR_S 1138, Centre de Recherche des Cordeliers, F-75006, Paris, France
| | - Amrit Singh-Estivalet
- INSERM, UMR_S 1138, Centre de Recherche des Cordeliers, F-75006, Paris, France
- Sorbonne Universités, UPMC, Univ Paris 06, UMR_S 1138, Centre de Recherche des Cordeliers, F-75006, Paris, France
- Université Paris Descartes, Sorbonne Paris Cité, UMR_S 1138, Centre de Recherche des Cordeliers, F-75006, Paris, France
| | - Jean-Marie Launay
- INSERM U942, Assistance Publique–Hôpitaux de Paris (AP-HP), Hôpital Lariboisière, Service de Biochimie, Paris, France
| | - Jacques Callebert
- INSERM U942, Assistance Publique–Hôpitaux de Paris (AP-HP), Hôpital Lariboisière, Service de Biochimie, Paris, France
| | - François Tronche
- Sorbonne Universités, UPMC, Univ Paris 06, UMR_S 1138, Centre de Recherche des Cordeliers, F-75006, Paris, France
- CNRS UMR INSERM 952-CNRS 7224, Paris, France
| | - Pascal Ferré
- INSERM, UMR_S 1138, Centre de Recherche des Cordeliers, F-75006, Paris, France
- Sorbonne Universités, UPMC, Univ Paris 06, UMR_S 1138, Centre de Recherche des Cordeliers, F-75006, Paris, France
- Université Paris Descartes, Sorbonne Paris Cité, UMR_S 1138, Centre de Recherche des Cordeliers, F-75006, Paris, France
| | - Jean-François Gautier
- INSERM, UMR_S 1138, Centre de Recherche des Cordeliers, F-75006, Paris, France
- Sorbonne Universités, UPMC, Univ Paris 06, UMR_S 1138, Centre de Recherche des Cordeliers, F-75006, Paris, France
- Université Paris Descartes, Sorbonne Paris Cité, UMR_S 1138, Centre de Recherche des Cordeliers, F-75006, Paris, France
- Department of Diabetes and Endocrinology, Hôpital Lariboisière, AP-HP, Paris, France
- Université Paris Diderot, Paris, France
| | - Ghislaine Guillemain
- INSERM, UMR_S 1138, Centre de Recherche des Cordeliers, F-75006, Paris, France
- Sorbonne Universités, UPMC, Univ Paris 06, UMR_S 1138, Centre de Recherche des Cordeliers, F-75006, Paris, France
- Université Paris Descartes, Sorbonne Paris Cité, UMR_S 1138, Centre de Recherche des Cordeliers, F-75006, Paris, France
| | - Bernadette Bréant
- INSERM, UMR_S 1138, Centre de Recherche des Cordeliers, F-75006, Paris, France
- Sorbonne Universités, UPMC, Univ Paris 06, UMR_S 1138, Centre de Recherche des Cordeliers, F-75006, Paris, France
- Université Paris Descartes, Sorbonne Paris Cité, UMR_S 1138, Centre de Recherche des Cordeliers, F-75006, Paris, France
| | - Bertrand Blondeau
- INSERM, UMR_S 1138, Centre de Recherche des Cordeliers, F-75006, Paris, France
- Sorbonne Universités, UPMC, Univ Paris 06, UMR_S 1138, Centre de Recherche des Cordeliers, F-75006, Paris, France
- Université Paris Descartes, Sorbonne Paris Cité, UMR_S 1138, Centre de Recherche des Cordeliers, F-75006, Paris, France
- * E-mail:
| | - Jean-Pierre Riveline
- INSERM, UMR_S 1138, Centre de Recherche des Cordeliers, F-75006, Paris, France
- Sorbonne Universités, UPMC, Univ Paris 06, UMR_S 1138, Centre de Recherche des Cordeliers, F-75006, Paris, France
- Université Paris Descartes, Sorbonne Paris Cité, UMR_S 1138, Centre de Recherche des Cordeliers, F-75006, Paris, France
- Department of Diabetes and Endocrinology, Hôpital Lariboisière, AP-HP, Paris, France
| |
Collapse
|
72
|
Abstract
Regulatory T cell (Treg) therapy has shown promises in experimental models of type 1 diabetes (T1D) and other autoimmune diseases. Now, Bluestone et al. (2015) report in a phase 1, dose-escalation study that ex vivo-expanded autologous polyclonal Treg therapy is safe and well tolerated in adult patients with recent-onset T1D.
Collapse
Affiliation(s)
- Jagadeesh Bayry
- Institut National de la Santé et de la Recherche Médicale Unité 1138, Paris 75006, France; Sorbonne Universités, UPMC Univ Paris 06, UMR S 1138, Paris 75006, France; Université Paris Descartes, Sorbonne Paris Cité, UMR S 1138, Paris 75006, France; Centre de Recherche des Cordeliers, Equipe - Immunopathologie et immuno-intervention thérapeutique, Paris 75006, France.
| | - Jean-François Gautier
- Institut National de la Santé et de la Recherche Médicale Unité 1138, Paris 75006, France; Sorbonne Universités, UPMC Univ Paris 06, UMR S 1138, Paris 75006, France; Université Paris Descartes, Sorbonne Paris Cité, UMR S 1138, Paris 75006, France; Centre de Recherche des Cordeliers, Equipe - Pathogenèse cellulaire et clinique du diabète, Paris 75006, France; Service de Diabétologie, Endocrinologie, Nutrition, Centre Universitaire du Diabète et de ses Complications, Hôpital Lariboisière, University Paris-Diderot Paris-7, Paris 75010, France
| |
Collapse
|
73
|
Baz B, Riveline JP, Gautier JF. ENDOCRINOLOGY OF PREGNANCY: Gestational diabetes mellitus: definition, aetiological and clinical aspects. Eur J Endocrinol 2016; 174:R43-51. [PMID: 26431552 DOI: 10.1530/eje-15-0378] [Citation(s) in RCA: 147] [Impact Index Per Article: 18.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/09/2015] [Accepted: 09/24/2015] [Indexed: 12/12/2022]
Abstract
Gestational diabetes (GDM) is defined as a glucose intolerance resulting in hyperglycaemia of variable severity with onset during pregnancy. This review aims to revisit the pathogenesis and aetiology of GDM in order to better understand its clinical presentation and outcomes. During normal pregnancy, insulin sensitivity declines with advancing gestation. These modifications are due to placental factors, progesterone and estrogen. In a physiological situation, a compensatory increase in insulin secretion maintains a normal glucose homeostasis. GDM occurs if pancreatic β-cells are unable to face the increased insulin demand during pregnancy. GDM is most commonly a forerunner of type 2 diabetes (T2D) - the most prevalent form of diabetes. These women share similar characteristics with predisposed subjects to T2D: insulin resistance before and after pregnancy, and carry more T2D risk alleles. Auto-immune and monogenic diabetes are more rare aetiologies of GDM. Adverse pregnancy outcomes of GDM are mainly related to macrosomia caused by fetal hyperinsulinism in response to high glucose levels coming from maternal hyperglycaemia. Screening recommendations and diagnosis criteria of GDM have been recently updated. High risk patients should be screened as early as possible using fasting plasma glucose, and if normal, at 24-28 weeks of gestation using 75 g oral glucose tolerance test. The treatment of GDM is based on education with trained nurses and dieticians, and if necessary insulin therapy.
Collapse
Affiliation(s)
- Baz Baz
- Department of Diabetes and EndocrinologyAssistance Publique - Hôpitaux de Paris, DHU FIRE, Lariboisière Hospital, Paris-Diderot University - Paris 7, 2, Rue Ambroise Paré, 75010 Paris, France
| | - Jean-Pierre Riveline
- Department of Diabetes and EndocrinologyAssistance Publique - Hôpitaux de Paris, DHU FIRE, Lariboisière Hospital, Paris-Diderot University - Paris 7, 2, Rue Ambroise Paré, 75010 Paris, France
| | - Jean-François Gautier
- Department of Diabetes and EndocrinologyAssistance Publique - Hôpitaux de Paris, DHU FIRE, Lariboisière Hospital, Paris-Diderot University - Paris 7, 2, Rue Ambroise Paré, 75010 Paris, France
| |
Collapse
|
74
|
Hadjadj S, Cariou B, Fumeron F, Gand E, Charpentier G, Roussel R, Kasmi AA, Gautier JF, Mohammedi K, Gourdy P, Saulnier PJ, Feigerlova E, Marre M. Death, end-stage renal disease and renal function decline in patients with diabetic nephropathy in French cohorts of type 1 and type 2 diabetes. Diabetologia 2016; 59:208-216. [PMID: 26486355 DOI: 10.1007/s00125-015-3785-3] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/29/2015] [Accepted: 09/15/2015] [Indexed: 10/22/2022]
Abstract
AIMS/HYPOTHESIS Microvascular complications are a common feature of diabetes but additional research is needed regarding diabetic nephropathy endpoints in type 1 and type 2 diabetes. METHODS We compared 277 type 1 diabetes patients with 942 type 2 diabetes patients, with clinical proteinuria and no endstage renal disease (ESRD) at baseline, prospectively followed for death, ESRD and decline in estimated glomerular filtration rate (eGFR, all available measures). RESULTS The incidence rate of death was 67.0 (95% CI 59.2, 74.8) vs. 24.6 (95% CI, 19.0, 30.2) per 1,000 patient-years, in type 2 diabetes and type 1 diabetes, respectively. Unadjusted risk for death was greater for type 2 diabetes patients (HR 3.423; 95% CI, 2.501, 4.683; p<0.0001), but the difference did not persist after adjustment for age (HRage-adj 0.859; 95% CI 0.581, 1.269; p=0.445). The incidence rate of ESRD was 18.4 (95% CI 14.2, 22.5) vs. 47.1 (95%CI 38.4, 55.9) per 1,000 patient-years, in type 2 diabetes and type 1 diabetes, respectively. Unadjusted risk for ESRD was lower in type 2 diabetes (HR 0.399; 95% CI 0.287, 0.554; p<0.0001), but the difference did not persist after adjustment for sex, age and baseline serum creatinine (HRadj 0.989; 95% CI 0.597, 1.639; p=0.965). In a mixed linear model, eGFR decline was not significantly different in type 2 vs. type 1 diabetes (difference in slope −0.19 [0.28] ml min(−1) 1.73 m(−2) year(−1); p=0.512). CONCLUSIONS/INTERPRETATION In diabetic nephropathy, once baseline risk factors were taken into account the risk for death, ESRD and renal function decline did not significantly differ between type 1 diabetes and type 2 diabetes.
Collapse
Affiliation(s)
- Samy Hadjadj
- Université de Poitiers, UFR Médecine Pharmacie, Centre d'Investigation clinique, Poitiers, France.
- CHU de Poitiers, Service d'Endocrinologie-Diabetologie, Rue de la milétrie, 86000, Poitiers, France.
- CHU de Poitiers, Centre d'Investigation Clinique, Poitiers, France.
- Inserm, CIC1402 and U1082, Poitiers, France.
- CHU de Poitiers, Service d'Endocrinologie-Diabetologie and Centre d'Investigation Clinique, Rue de la Milétrie, 86000, Poitiers, France.
| | - Bertrand Cariou
- Department of Endocrinology, University Hospital of Nantes, Nantes, France
- Inserm, UMR1087-CNRS UMR6291, Institut du Thorax, Nantes, France
| | - Frederic Fumeron
- Université Paris Diderot, Sorbonne Paris Cité, Paris, France
- Inserm, UMRS1138, Centre de Recherche des Cordeliers, Paris, France
- Diabetologie, Endocrinologie Nutrition, DHU FIRE, Hopital Bichat, AP-HP, Paris, France
| | - Elise Gand
- CHU de Poitiers, Pôle Dune, Poitiers, France
| | | | - Ronan Roussel
- Université Paris Diderot, Sorbonne Paris Cité, Paris, France
- Inserm, UMRS1138, Centre de Recherche des Cordeliers, Paris, France
- Diabetologie, Endocrinologie Nutrition, DHU FIRE, Hopital Bichat, AP-HP, Paris, France
| | - Ahmed-Amine Kasmi
- Université de Poitiers, UFR Médecine Pharmacie, Centre d'Investigation clinique, Poitiers, France
- CHU de Poitiers, Centre d'Investigation Clinique, Poitiers, France
- Inserm, CIC1402 and U1082, Poitiers, France
| | - Jean-François Gautier
- Université Paris Diderot, Sorbonne Paris Cité, Paris, France
- Inserm, UMRS1138, Centre de Recherche des Cordeliers, Paris, France
- Department of Diabetes and Endocrinology, Assistance Publique - Hôpitaux de Paris, Lariboisière Hospital, Paris, France
| | - Kammel Mohammedi
- Université Paris Diderot, Sorbonne Paris Cité, Paris, France
- Inserm, UMRS1138, Centre de Recherche des Cordeliers, Paris, France
- Diabetologie, Endocrinologie Nutrition, DHU FIRE, Hopital Bichat, AP-HP, Paris, France
| | - Pierre Gourdy
- CHU de Toulouse, Service de Diabétologie, Maladies Métaboliques et Nutrition, Toulouse, France
- Inserm, UMR1048/I2MC, Toulouse, France
- Université Paul Sabatier, UMR1048/I2MC, Toulouse, France
| | - Pierre-Jean Saulnier
- Université de Poitiers, UFR Médecine Pharmacie, Centre d'Investigation clinique, Poitiers, France
- CHU de Poitiers, Service d'Endocrinologie-Diabetologie, Rue de la milétrie, 86000, Poitiers, France
- CHU de Poitiers, Centre d'Investigation Clinique, Poitiers, France
- Inserm, CIC1402 and U1082, Poitiers, France
| | - Eva Feigerlova
- Université de Poitiers, UFR Médecine Pharmacie, Centre d'Investigation clinique, Poitiers, France
- CHU de Poitiers, Service d'Endocrinologie-Diabetologie, Rue de la milétrie, 86000, Poitiers, France
- CHU de Poitiers, Centre d'Investigation Clinique, Poitiers, France
- Inserm, CIC1402 and U1082, Poitiers, France
| | - Michel Marre
- Université Paris Diderot, Sorbonne Paris Cité, Paris, France
- Inserm, UMRS1138, Centre de Recherche des Cordeliers, Paris, France
- Diabetologie, Endocrinologie Nutrition, DHU FIRE, Hopital Bichat, AP-HP, Paris, France
| | | |
Collapse
|
75
|
Gautier JF, Porcher R, Abi Khalil C, Bellili-Munoz N, Fetita LS, Travert F, Choukem SP, Riveline JP, Hadjadj S, Larger E, Boudou P, Blondeau B, Roussel R, Ferré P, Ravussin E, Rouzet F, Marre M. Kidney Dysfunction in Adult Offspring Exposed In Utero to Type 1 Diabetes Is Associated with Alterations in Genome-Wide DNA Methylation. PLoS One 2015; 10:e0134654. [PMID: 26258530 PMCID: PMC4530883 DOI: 10.1371/journal.pone.0134654] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2014] [Accepted: 07/13/2015] [Indexed: 12/20/2022] Open
Abstract
Background Fetal exposure to hyperglycemia impacts negatively kidney development and function. Objective Our objective was to determine whether fetal exposure to moderate hyperglycemia is associated with epigenetic alterations in DNA methylation in peripheral blood cells and whether those alterations are related to impaired kidney function in adult offspring. Design Twenty nine adult, non-diabetic offspring of mothers with type 1 diabetes (T1D) (case group) were matched with 28 offspring of T1D fathers (control group) for the study of their leukocyte genome-wide DNA methylation profile (27,578 CpG sites, Human Methylation 27 BeadChip, Illumina Infinium). In a subset of 19 cases and 18 controls, we assessed renal vascular development by measuring Glomerular Filtration Rate (GFR) and Effective Renal Plasma Flow (ERPF) at baseline and during vasodilatation produced by amino acid infusion. Results Globally, DNA was under-methylated in cases vs. controls. Among the 87 CpG sites differently methylated, 74 sites were less methylated and 13 sites more methylated in cases vs. controls. None of these CpG sites were located on a gene known to be directly involved in kidney development and/or function. However, the gene encoding DNA methyltransferase 1 (DNMT1)—a key enzyme involved in gene expression during early development–was under-methylated in cases. The average methylation of the 74 under-methylated sites differently correlated with GFR in cases and controls. Conclusion Alterations in methylation profile imprinted by the hyperglycemic milieu of T1D mothers during fetal development may impact kidney function in adult offspring. The involved pathways seem to be a nonspecific imprinting process rather than specific to kidney development or function.
Collapse
Affiliation(s)
- Jean-François Gautier
- Department of Diabetes and Endocrinology, Assistance Publique—Hôpitaux de Paris, DHU FIRE, Lariboisière Hospital, University Paris-Diderot Paris-7, Paris, France
- Clinical Investigation Center, INSERM-CIC9504, Saint-Louis University Hospital, Assistance Publique—Hôpitaux de Paris, University Paris-Diderot Paris-7, Paris, France
- INSERM UMRS 1138, Cordeliers Research Center, University Pierre et Marie Curie Paris-6, Paris, France
- * E-mail:
| | - Raphaël Porcher
- Department of Biostatistics and Medical Computing, Saint-Louis University Hospital, Assistance Publique—Hôpitaux de Paris, University Paris-Diderot Paris-7, Paris, France
| | - Charbel Abi Khalil
- Department of Diabetes, Groupe Hospitalier Bichat—Claude Bernard, Assistance Publique—Hôpitaux de Paris, DHU FIRE, University Paris-Diderot Paris-7, Paris, France
| | - Naima Bellili-Munoz
- INSERM UMRS 1138, Cordeliers Research Center, University Pierre et Marie Curie Paris-6, Paris, France
| | - Lila Sabrina Fetita
- Department of Diabetes and Endocrinology, Assistance Publique—Hôpitaux de Paris, DHU FIRE, Lariboisière Hospital, University Paris-Diderot Paris-7, Paris, France
| | - Florence Travert
- Department of Diabetes, Groupe Hospitalier Bichat—Claude Bernard, Assistance Publique—Hôpitaux de Paris, DHU FIRE, University Paris-Diderot Paris-7, Paris, France
- Clinical Investigation Center, Groupe Hospitalier Bichat—Claude Bernard, Assistance Publique–Hôpitaux de Paris, University Paris-Diderot Paris-7, Paris, France
| | - Simeon-Pierre Choukem
- Department of Diabetes and Endocrinology, Assistance Publique—Hôpitaux de Paris, DHU FIRE, Lariboisière Hospital, University Paris-Diderot Paris-7, Paris, France
| | - Jean-Pierre Riveline
- INSERM UMRS 1138, Cordeliers Research Center, University Pierre et Marie Curie Paris-6, Paris, France
- Department of Diabetes and Endocrinology, Centre Hospitalier Sud Francilien, Corbeil-Essonnes, France
| | - Samy Hadjadj
- Department of Endocrinology and Diabetes, Centre Hospitalier Universitaire, Poitiers, France
| | - Etienne Larger
- Department of Diabetes, Hôtel-Dieu Hospital, Assistance Publique–Hôpitaux de Paris, Paris, France
| | - Philippe Boudou
- Unit of Transfer in Molecular Oncology and Hormonology, Saint-Louis University Hospital, Assistance Publique—Hôpitaux de Paris, Paris, France
| | - Bertrand Blondeau
- INSERM UMRS 1138, Cordeliers Research Center, University Pierre et Marie Curie Paris-6, Paris, France
| | - Ronan Roussel
- Department of Diabetes, Groupe Hospitalier Bichat—Claude Bernard, Assistance Publique—Hôpitaux de Paris, DHU FIRE, University Paris-Diderot Paris-7, Paris, France
- INSERM U695, University Paris-Diderot Paris-7, Paris, France
| | - Pascal Ferré
- INSERM UMRS 1138, Cordeliers Research Center, University Pierre et Marie Curie Paris-6, Paris, France
| | - Eric Ravussin
- Penington Biomedical Research Center, Baton Rouge, LA, United States of America
| | - François Rouzet
- Department of Nuclear Medicine, Groupe Hospitalier Bichat—Claude Bernard, Assistance Publique—Hôpitaux de Paris, University Paris-Diderot Paris-7, Paris, France
| | - Michel Marre
- Department of Diabetes, Groupe Hospitalier Bichat—Claude Bernard, Assistance Publique—Hôpitaux de Paris, DHU FIRE, University Paris-Diderot Paris-7, Paris, France
- Clinical Investigation Center, Groupe Hospitalier Bichat—Claude Bernard, Assistance Publique–Hôpitaux de Paris, University Paris-Diderot Paris-7, Paris, France
- INSERM U695, University Paris-Diderot Paris-7, Paris, France
| |
Collapse
|
76
|
Affiliation(s)
- Clara H Bouché
- Department of Diabetes and Endocrinology, Assistance Publique - Hôpitaux de Paris, DHU FIRE, Lariboisière Hospital University Paris-Diderot Paris-7, 75010 Paris, France, and INSERM UMRS 1138, Cordeliers Research Centre, 75006, Paris, France
| | - Jean-Pierre Garnier
- Biochemistry Laboratory, Saint-Louis University Hospital, Assistance Publique - Hôpitaux de Paris, University Paris Descartes, 75010 Paris, France
| | - Siméon-Pierre Choukem
- Department of Diabetes and Endocrinology, Assistance Publique - Hôpitaux de Paris, DHU FIRE, Lariboisière Hospital University Paris-Diderot Paris-7, 75010 Paris, France, and INSERM UMRS 1138, Cordeliers Research Centre, 75006, Paris, France
| | - Jean-François Gautier
- Department of Diabetes and Endocrinology, Assistance Publique - Hôpitaux de Paris, DHU FIRE, Lariboisière Hospital University Paris-Diderot Paris-7, 75010 Paris, France, and INSERM UMRS 1138, Cordeliers Research Centre, 75006, Paris, France
| |
Collapse
|
77
|
Gourdy P, Penfornis A, Charpentier G, Martinez L, Eschwège E, Madani S, Kienhöfer J, Kretzschmar Y, Gautier JF. Wirksamkeit und Verträglichkeit von Liraglutid bei Patienten mit Typ 2 Diabetes: 2-Jahresdaten der prospektiven EVIDENCE-Beobachtungsstudie. DIABETOL STOFFWECHS 2015. [DOI: 10.1055/s-0035-1549745] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
78
|
Balti EV, Ngo-Nemb MC, Lontchi-Yimagou E, Atogho-Tiedeu B, Effoe VS, Akwo EA, Dehayem MY, Mbanya JC, Gautier JF, Sobngwi E. Association of HLA class II markers with autoantibody-negative ketosis-prone atypical diabetes compared to type 2 diabetes in a population of sub-Saharan African patients. Diabetes Res Clin Pract 2015; 107:31-6. [PMID: 25511714 DOI: 10.1016/j.diabres.2014.10.002] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/04/2014] [Accepted: 10/18/2014] [Indexed: 10/24/2022]
Abstract
AIM We investigated the association of HLA DRB1 and DQB1 alleles, haplotypes and genotypes with unprovoked antibody-negative ketosis-prone atypical diabetes (A(-) KPD) in comparison to type 2 diabetes (T2D). METHODS A(-) KPD and T2D sub-Saharan African patients aged 19-63 years were consecutively recruited. Patients positive for cytoplasmic islet cell, insulin, glutamic acid decarboxylase or islet antigen-2 autoantibodies were excluded. Odds ratios were obtained via logistic regression after considering alleles with a minimum frequency of 5% in the study population. Bonferroni correction was used in the case of multiple comparisons. RESULTS Among the 130 participants, 35 (27%) were women and 57 (44%) were A(-) KPD. DRB1 and DQB1 allele frequencies were similar for both A(-) KPD and T2D patients; they did not confer any substantial risk even after considering type 1 diabetes susceptibility and resistance alleles. We found no association between A(-) KPD and the derived DRB1*07-DQB1*02:02 (OR: 0.55 [95%CI: 0.17-1.85], P=0.336); DRB1*11-DQB1*03:01 (OR: 2.42 [95%CI: 0.79-7.42], P=0.123); DRB1*15-DQB1*06:02 (OR: 0.87 [95%CI: 0.39-1.95], P=0.731) and DRB1*03:01-DQB1*02:01 (OR: 1.48 [95%CI: 0.55-3.96], P=0.437) haplotypes. Overall, we did not find any evidence of susceptibility to ketosis associated with DRB1 and DQB1 genotypes (all P>0.05) in A(-) KPD compared to T2D. Similar results were obtained after adjusting the analysis for age and sex. CONCLUSION Factors other than DRB1 and DQB1 genotype could explain the propensity to ketosis in A(-) KPD. These results need to be confirmed in a larger population with the perspective of improving the classification and understanding of the pathophysiology of A(-) KPD.
Collapse
Affiliation(s)
- Eric V Balti
- Diabetes Research Center, Brussels Free University-VUB, Brussels, Belgium; National Obesity Center, Yaounde Central Hospital and Faculty of Medicine and Biomedical Sciences, University of Yaounde 1, Yaounde, Cameroon
| | - Marinette C Ngo-Nemb
- National Obesity Center, Yaounde Central Hospital and Faculty of Medicine and Biomedical Sciences, University of Yaounde 1, Yaounde, Cameroon
| | - Eric Lontchi-Yimagou
- Molecular Medicine and Metabolism Laboratories, Biotechnology Center, University of Yaounde 1, Yaounde, Cameroon; Université Paris Diderot, Paris, France
| | - Barbara Atogho-Tiedeu
- Molecular Medicine and Metabolism Laboratories, Biotechnology Center, University of Yaounde 1, Yaounde, Cameroon
| | - Valery S Effoe
- National Obesity Center, Yaounde Central Hospital and Faculty of Medicine and Biomedical Sciences, University of Yaounde 1, Yaounde, Cameroon; Department of Epidemiology and Prevention, Wake Forest University School of Medicine, Winston-Salem, NC, USA
| | - Elvis A Akwo
- National Obesity Center, Yaounde Central Hospital and Faculty of Medicine and Biomedical Sciences, University of Yaounde 1, Yaounde, Cameroon; Department of Medicine, Vanderbilt University, Nashville, TN, USA
| | - Mesmin Y Dehayem
- National Obesity Center, Yaounde Central Hospital and Faculty of Medicine and Biomedical Sciences, University of Yaounde 1, Yaounde, Cameroon
| | - Jean-Claude Mbanya
- National Obesity Center, Yaounde Central Hospital and Faculty of Medicine and Biomedical Sciences, University of Yaounde 1, Yaounde, Cameroon; Molecular Medicine and Metabolism Laboratories, Biotechnology Center, University of Yaounde 1, Yaounde, Cameroon; University of Technology, Kingston, Jamaica
| | - Jean-François Gautier
- Université Paris Diderot, Paris, France; Department of Diabetes and Endocrinology, Saint-Louis Hospital, Paris, France; INSERM, UMRS 872, Cordeliers Research Center, Paris, France; Université Pierre et Marie Curie, Paris, France
| | - Eugene Sobngwi
- National Obesity Center, Yaounde Central Hospital and Faculty of Medicine and Biomedical Sciences, University of Yaounde 1, Yaounde, Cameroon; Molecular Medicine and Metabolism Laboratories, Biotechnology Center, University of Yaounde 1, Yaounde, Cameroon.
| |
Collapse
|
79
|
Rea D, Mirault T, Cluzeau T, Gautier JF, Guilhot F, Dombret H, Messas E. Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia. Haematologica 2014; 99:1197-203. [PMID: 24658819 DOI: 10.3324/haematol.2014.104075] [Citation(s) in RCA: 97] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Despite a well-recognized clinical benefit of the 2(nd)-generation tyrosine kinase inhibitor nilotinib in patients with imatinib-resistant/-intolerant or newly diagnosed chronic myeloid leukemia, recent evidence suggests that nilotinib has a propensity to increase the risk of occlusive arterial events, especially in patients with pre-existing cardiovascular risk factors. Given the key role of lipids in cardiovascular diseases, we studied the plasma lipid profile and global cardiovascular risk prior to and during nilotinib therapy in a series of 27 patients in the setting of a prospective single center study. Data from a minimum 1-year follow up showed that nilotinib significantly increased total, low- and high-density lipoprotein cholesterol within three months. Consequently, the proportion of patients with non-optimal low-density lipoprotein cholesterol increased from 48.1% to 88.9% by 12 months, leading to cholesterol-lowering drug intervention in 22.2% of patients. The proportion of patients with low levels of high-density lipoprotein cholesterol decreased from 40.7% to 7.4% by 12 months. In contrast, a significant decrease in triglycerides was observed. Global cardiovascular risk worsened in 11.1% of patients due to diabetes or occlusive arterial events. Whether hypercholesterolemia was the main driver of occlusive arterial events was uncertain: a longer follow up is necessary to ask whether nilotinib-induced hypercholesterolemia increases long-term risk of atherosclerotic diseases. Nevertheless, given key atherogenic properties of low-density lipoprotein cholesterol, we conclude that when prescribing nilotinib, commitment to detect lipid disorders at baseline and during follow up is mandatory given their frequency, requirement for changes in lifestyle or drug intervention, and potential for long-term cardiovascular complications.
Collapse
Affiliation(s)
- Delphine Rea
- Service d'Hématologie Adulte, Hôpital Saint-Louis, AP-HP, Paris
| | - Tristan Mirault
- Service de Médecine Vasculaire and INSERM UMR970, PARCC, Hôpital Européen Georges Pompidou, AP-HP, Paris
| | - Thomas Cluzeau
- Service d'Hématologie Adulte, Hôpital Saint-Louis, AP-HP, Paris
| | | | - François Guilhot
- INSERM Centre d'Investigation Clinique 1402, CHU de Poitiers, France
| | - Hervé Dombret
- Service d'Hématologie Adulte, Hôpital Saint-Louis, AP-HP, Paris
| | - Emmanuel Messas
- Service de Médecine Vasculaire and INSERM UMR970, PARCC, Hôpital Européen Georges Pompidou, AP-HP, Paris
| |
Collapse
|
80
|
Penfornis A, Gourdy P, Martinez L, Madani S, Charpentier G, Eschwège E, Gautier JF. Effect of Type 2 Diabetes Disease Stage on Liraglutide Response in Clinical Practice: Data from the EVIDENCE® Study. Can J Diabetes 2013. [DOI: 10.1016/j.jcjd.2013.08.116] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
81
|
Charpentier G, Martinez L, Eschwege E, Madani S, Penfornis A, Gourdy P, Gautier JF. Effectiveness of Liraglutide in Type 2 Diabetes Patients Switched from a DPP-4 Inhibitor: 1-Year Data from EVIDENCE®. Can J Diabetes 2013. [DOI: 10.1016/j.jcjd.2013.08.114] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
82
|
|
83
|
Berrou J, Fougeray S, Venot M, Chardiny V, Gautier JF, Dulphy N, Toubert A, Peraldi MN. Natural killer cell function, an important target for infection and tumor protection, is impaired in type 2 diabetes. PLoS One 2013; 8:e62418. [PMID: 23638076 PMCID: PMC3636194 DOI: 10.1371/journal.pone.0062418] [Citation(s) in RCA: 82] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2012] [Accepted: 03/24/2013] [Indexed: 02/07/2023] Open
Abstract
Patients with Type 2 diabetes (T2D) are highly susceptible to infection and have an increased incidence of some tumors, possibly due to immune system dysfunction. In the innate cellular immune system, Natural Killer (NK) lymphocytes are important effectors responsible for controlling infections and combating tumor development. We analyzed NK cell subsets in 51 patients with long-standing T2D. Compared with healthy blood donors, diabetic patients showed a profound decrease in both NKG2D-positive NK cells (44% vs. 55.5%, P<0.01) and NKp46-positive cells (26% vs. 50%, P<0.01). Decreased expression of these receptors was associated with functional defects, such as reduced NK degranulation capacity when challenged with the tumor target cell line K562 (10.3 vs. 15.8%, P<0.05). This defect could be restored in vitro by stimulating NK cells from T2D patients with IL-15 (P<0.05). NKG2D expression was found to be negatively correlated with HBA1c level (r=-0.50; P=0.009), suggesting that sustained hyperglycemia could directly influence NK cell defects. We demonstrated that endoplasmic reticulum (ER) stress, an important mediator in diabetes-associated complications, was inducible in vitro in normal NK cells and that tunicamycin treatment resulted in a significant decrease in NKG2D expression (P<0.05). Furthermore, markers of the Unfolded Protein Response (UPR) BiP, PDI and sXBP1 mRNAs were significantly increased in NK cells from T2D patients (P<0.05, P<0.01, P<0.05, respectively), indicating that ER stress is activated in vivo through both PERK and IRE1 sensors. These results demonstrate for the first time defects in NK cell-activating receptors NKG2D and NKp46 in T2D patients, and implicate the UPR pathway as a potential mechanism. These defects may contribute to susceptibility to infections and malignancies and could be targetted therapeutically.
Collapse
Affiliation(s)
- Jeannig Berrou
- Institut National de la Santé et de la Recherche Médicale (INSERM), UMR 940, Paris, France
- Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Saint-Louis Centre d’Investigations Biomédicales “H-O-G”, Paris, France
| | - Sophie Fougeray
- INSERM U775, Centre Universitaire des Saints Pères, Paris, France
- Université Paris Descartes, Sorbonne Paris Cité, Paris, France
| | - Marion Venot
- Institut National de la Santé et de la Recherche Médicale (INSERM), UMR 940, Paris, France
| | - Victor Chardiny
- Institut National de la Santé et de la Recherche Médicale (INSERM), UMR 940, Paris, France
| | - Jean-François Gautier
- AP-HP, Hôpital Saint-Louis, Department of Diabetes and Endocrinology, Paris, France
- Université Paris 7-Denis Diderot, Sorbonne Paris Cité, Paris, France
| | - Nicolas Dulphy
- Institut National de la Santé et de la Recherche Médicale (INSERM), UMR 940, Paris, France
- Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Saint-Louis Centre d’Investigations Biomédicales “H-O-G”, Paris, France
- Université Paris 7-Denis Diderot, Sorbonne Paris Cité, Paris, France
- Université Paris Diderot, Sorbonne Paris Cité, Institut Universitaire d’Hématologie, Paris, France
| | - Antoine Toubert
- Institut National de la Santé et de la Recherche Médicale (INSERM), UMR 940, Paris, France
- Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Saint-Louis Centre d’Investigations Biomédicales “H-O-G”, Paris, France
- Université Paris 7-Denis Diderot, Sorbonne Paris Cité, Paris, France
- Université Paris Diderot, Sorbonne Paris Cité, Institut Universitaire d’Hématologie, Paris, France
| | - Marie-Noëlle Peraldi
- Institut National de la Santé et de la Recherche Médicale (INSERM), UMR 940, Paris, France
- Université Paris 7-Denis Diderot, Sorbonne Paris Cité, Paris, France
- AP-HP, Hôpital Saint-Louis, Nephrology and Transplantation Department Paris, France
| |
Collapse
|
84
|
Valtat B, Riveline JP, Zhang P, Singh-Estivalet A, Armanet M, Venteclef N, Besseiche A, Kelly DP, Tronche F, Ferré P, Gautier JF, Bréant B, Blondeau B. Fetal PGC-1α overexpression programs adult pancreatic β-cell dysfunction. Diabetes 2013; 62:1206-16. [PMID: 23274887 PMCID: PMC3609553 DOI: 10.2337/db12-0314] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Adult β-cell dysfunction, a hallmark of type 2 diabetes, can be programmed by adverse fetal environment. We have shown that fetal glucocorticoids (GCs) participate in this programming through inhibition of β-cell development. Here we have investigated the molecular mechanisms underlying this regulation. We showed that GCs stimulate the expression of peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α), a coregulator of the GCs receptor (GR), and that the overexpression of PGC-1α represses genes important for β-cell development and function. More precisely, PGC-1α inhibited the expression of the key β-cell transcription factor pancreatic duodenal homeobox 1 (Pdx1). This repression required the GR and was mediated through binding of a GR/PGC-1α complex to the Pdx1 promoter. To explore PGC-1α function, we generated mice with inducible β-cell PGC-1α overexpression. Mice overexpressing PGC-1α exhibited at adult age impaired glucose tolerance associated with reduced insulin secretion, decreased β-cell mass, and β-cell hypotrophy. Interestingly, PGC-1α expression in fetal life only was sufficient to impair adult β-cell function whereas β-cell PGC-1α overexpression from adult age had no consequence on β-cell function. Altogether, our results demonstrate that the GR and PGC-1α participate in the fetal programming of adult β-cell function through inhibition of Pdx1 expression.
Collapse
Affiliation(s)
- Bérengère Valtat
- INSERM, UMRS 872, Cordeliers Research Center, Paris, France
- Université Pierre et Marie Curie, Paris, France
| | - Jean-Pierre Riveline
- INSERM, UMRS 872, Cordeliers Research Center, Paris, France
- Université Pierre et Marie Curie, Paris, France
| | - Ping Zhang
- INSERM, UMRS 872, Cordeliers Research Center, Paris, France
- Université Pierre et Marie Curie, Paris, France
| | - Amrit Singh-Estivalet
- INSERM, UMRS 872, Cordeliers Research Center, Paris, France
- Université Pierre et Marie Curie, Paris, France
| | - Mathieu Armanet
- INSERM, UMRS 872, Cordeliers Research Center, Paris, France
- Université Pierre et Marie Curie, Paris, France
- Cell Therapy Unit, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, Paris, France
| | - Nicolas Venteclef
- INSERM, UMRS 872, Cordeliers Research Center, Paris, France
- Université Pierre et Marie Curie, Paris, France
| | - Adrien Besseiche
- INSERM, UMRS 872, Cordeliers Research Center, Paris, France
- Université Pierre et Marie Curie, Paris, France
| | - Daniel P. Kelly
- Sanford-Burnham Medical Research Institute, Orlando, Florida
| | - François Tronche
- Université Pierre et Marie Curie, Paris, France
- CNRS UMR INSERM 952-CNRS 7224, Paris, France
| | - Pascal Ferré
- INSERM, UMRS 872, Cordeliers Research Center, Paris, France
- Université Pierre et Marie Curie, Paris, France
| | - Jean-François Gautier
- INSERM, UMRS 872, Cordeliers Research Center, Paris, France
- Université Pierre et Marie Curie, Paris, France
- Department of Diabetes and Endocrinology, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris, Paris, France
- Université Paris Diderot, Paris, France
| | - Bernadette Bréant
- INSERM, UMRS 872, Cordeliers Research Center, Paris, France
- Université Pierre et Marie Curie, Paris, France
| | - Bertrand Blondeau
- INSERM, UMRS 872, Cordeliers Research Center, Paris, France
- Université Pierre et Marie Curie, Paris, France
- Corresponding author: Bertrand Blondeau,
| |
Collapse
|
85
|
Choukem SP, Sobngwi E, Boudou P, Fetita LS, Porcher R, Ibrahim F, Blondeau B, Vexiau P, Mauvais-Jarvis F, Calvo F, Gautier JF. β- and α-cell dysfunctions in africans with ketosis-prone atypical diabetes during near-normoglycemic remission. Diabetes Care 2013; 36:118-23. [PMID: 22933436 PMCID: PMC3526247 DOI: 10.2337/dc12-0798] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
OBJECTIVE Ketosis-prone atypical diabetes (KPD) is a subtype of diabetes in which the pathophysiology is yet to be unraveled. The aim of this study was to characterize β- and α-cell functions in Africans with KPD during remission. RESEARCH DESIGN AND METHODS We characterized β- and α-cell functions in Africans with KPD during remission. The cohort comprised 15 sub-Saharan Africans who had been insulin-free for a median of 6 months. Patients in remission were in good glycemic control (near-normoglycemic) and compared with 15 nondiabetic control subjects matched for age, sex, ethnicity, and BMI. Plasma insulin, C-peptide, and glucagon concentrations were measured in response to oral and intravenous glucose and to combined intravenous arginine and glucose. Early insulin secretion was measured during a 75-g oral glucose tolerance test. Insulin secretion rate and glucagon were assessed in response to intravenous glucose ramping. RESULTS Early insulin secretion and maximal insulin secretion rate were lower in patients compared with control participants. In response to combined arginine and glucose stimulation, maximal insulin response was reduced. Glucagon suppression was also decreased in response to oral and intravenous glucose but not in response to arginine and insulin. CONCLUSIONS Patients with KPD in protracted near-normoglycemic remission have impaired insulin response to oral and intravenous glucose and to arginine, as well as impaired glucagon suppression. Our results suggest that β- and α-cell dysfunctions both contribute to the pathophysiology of KPD.
Collapse
Affiliation(s)
- Siméon-Pierre Choukem
- Department of Diabetes and Endocrinology, Saint-Louis University Hospital, Assistance Publique–Hôpitaux de Paris, University Paris-Diderot Paris-7, Paris, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
86
|
Abstract
Recombinant methionyl human leptin (r-metHuLeptin) was first used as a replacement therapy in patients bearing inactivating mutations in the leptin gene. In this indication, it was shown since 1999 to be very efficient in inducing a dramatic weight loss in rare children and adults with severe obesity due to the lack of leptin. These first clinical trials clearly showed that r-metHuLeptin acted centrally to reduce food intake, inducing loss of fat mass, and to correct metabolic alterations, immune and neuroendocrine defects. A few years later, r-metHuLeptin was also shown to reverse the metabolic complications associated with lipodystrophic syndromes, due to primary defects in fat storage, which induce leptin deficiency. The beneficial effects, which could be mediated by central and/or peripheral mechanisms, are thought to mainly involve the lowering effects of leptin on ectopic lipid storage, in particular in liver and muscles, reducing insulin resistance. Interestingly, r-metHuLeptin therapy also reversed the hypothalamic-pituitary-gonadal axis dysfunctions associated with hypothalamic amenorrhea. However, if r-metHuLeptin treatment has been shown to be dramatically efficient in leptin-deficient states, its very limited effect in inducing weight loss in common obese patients revealed that, in patients with adequate leptin secretion, mechanisms of leptin resistance and leptin tolerance prevent r-metHuLeptin from inducing any additional effects. This review will present the current data about the effects of r-metHuLeptin therapy in humans, and discuss the recent perspectives of this therapy in new indications.
Collapse
Affiliation(s)
- Camille Vatier
- INSERM, UMR_S938, Centre de Recherches Saint-Antoine, Paris F-75012, France.
| | | | | |
Collapse
|
87
|
Riveline JP, Rousseau E, Reznik Y, Fetita S, Philippe J, Dechaume A, Hartemann A, Polak M, Petit C, Charpentier G, Gautier JF, Froguel P, Vaxillaire M. Clinical and metabolic features of adult-onset diabetes caused by ABCC8 mutations. Diabetes Care 2012; 35:248-51. [PMID: 22210575 PMCID: PMC3263906 DOI: 10.2337/dc11-1469] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
OBJECTIVE Gain-of-function ABCC8/sulfonylurea (SU) receptor 1 mutations cause neonatal diabetes mellitus (NDM) or late-onset diabetes in adult relatives. Given the effectiveness of SU treatment in ABCC8-NDM patients, we further characterized late-onset ABCC8-associated diabetes. RESEARCH DESIGN AND METHODS Seven adult subjects from three NDM families and one family with type 2 diabetes were studied. Insulin secretion and insulin sensitivity were assessed using clamp techniques. We screened 139 type 2 diabetic patients who were well controlled by SU for ABCC8 mutations. RESULTS ABCC8 mutation carriers exhibited glucose intolerance, frank diabetes, or insulin-requiring diabetes since diagnosis. HbA(1c) improved in five SU-treated patients. Insulin secretion capacity was impaired in three patients compared with adult control subjects but was restored after a 4-week SU trial in two patients. Cohort screening revealed four SU-treated patients with ABCC8 mutations, two of which are likely causal. CONCLUSIONS Although of rare occurrence, recognition of adult-onset ABCC8-associated diabetes may help in targeting patients for SU therapy.
Collapse
Affiliation(s)
- Jean-Pierre Riveline
- Department of Diabetes and Endocrinology, Centre Hospitalier Sud Francilien, Corbeil-Essonnes, France.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
88
|
Kamenický P, Droumaguet C, Salenave S, Blanchard A, Jublanc C, Gautier JF, Brailly-Tabard S, Leboulleux S, Schlumberger M, Baudin E, Chanson P, Young J. Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome. J Clin Endocrinol Metab 2011; 96:2796-804. [PMID: 21752886 DOI: 10.1210/jc.2011-0536] [Citation(s) in RCA: 134] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
CONTEXT Mitotane is highly effective in the long-term management of Cushing's syndrome but has a slow onset of action. Mitotane combined with fast-acting steroidogenesis inhibitors might avoid the need for emergency bilateral adrenalectomy in patients with severe hypercortisolism. OBJECTIVE Our objective was to assess the efficacy and safety of combination therapy with mitotane, metyrapone, and ketoconazole in severe ACTH-dependent Cushing's syndrome. PATIENTS, DESIGN, AND SETTING Eleven patients with severe Cushing's syndrome participated in this follow-up study in a tertiary referral hospital. INTERVENTIONS High-dose therapy combining mitotane (3.0-5.0 g/24 h), metyrapone (3.0-4.5 g/24 h), and ketoconazole (400-1200 mg/24 h) was initiated concomitantly. Twenty-four-hour urinary free cortisol (UFC) excretion (normal values 10-65 μg/24 h) was monitored. RESULTS Data are reported as medians (range). All 11 patients experienced a marked clinical improvement. UFC excretion fell rapidly from 2737 μg/24 h (range 853-22,605) at baseline to 50 μg/24 h (range 18-298) (P = 0.001) within 24-48 h of treatment initiation and remained low to normal on the combination therapy. In seven patients, metyrapone and ketoconazole were discontinued after 3.5 months (range 3.0-6.0) of combination therapy, and UFC excretion remained controlled by mitotane monotherapy (UFC 17 μg/24 h, range 5-85; P = 0.016). Five patients became able to undergo etiological surgery and are presently in remission. Four of them recovered normal adrenal function after mitotane discontinuation. Adverse effects were tolerable, consisting mainly of gastrointestinal discomfort and a significant rise in total cholesterol and γ-glutamyl transferase levels (P = 0.012 and P = 0.002, respectively). CONCLUSIONS When surgical treatment for severe ACTH-dependent Cushing's syndrome is not feasible, combination therapy with mitotane, metyrapone, and ketoconazole is an effective alternative to bilateral adrenalectomy, a procedure associated with significant morbidity and permanent hypoadrenalism.
Collapse
Affiliation(s)
- Peter Kamenický
- Faculté de Médecine Paris-Sud, Unité Mixte de Recherche S693, and Institut National de la Santé et de la Recherche Médicale Unité 693, Université Paris-Sud, Le Kremlin Bicêtre F-94276, France
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
89
|
Bellanné-Chantelot C, Lévy DJ, Carette C, Saint-Martin C, Riveline JP, Larger E, Valéro R, Gautier JF, Reznik Y, Sola A, Hartemann A, Laboureau-Soares S, Laloi-Michelin M, Lecomte P, Chaillous L, Dubois-Laforgue D, Timsit J. Clinical characteristics and diagnostic criteria of maturity-onset diabetes of the young (MODY) due to molecular anomalies of the HNF1A gene. J Clin Endocrinol Metab 2011; 96:E1346-51. [PMID: 21677039 DOI: 10.1210/jc.2011-0268] [Citation(s) in RCA: 53] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
CONTEXT The diagnosis of maturity-onset diabetes of the young type 3 (MODY3), associated with HNF1A molecular abnormalities, is often missed. OBJECTIVE The objective of the study was to describe the phenotypes of a large series of MODY3 patients and to reassess parameters that may improve its diagnosis. DESIGN, SETTING, AND PATIENTS This retrospective multicenter study included 487 unrelated patients referred because of suspicion of MODY3. Genetic analysis identified 196 MODY3 and 283 non-MODY3 cases. Criteria associated with MODY3 were assessed by multivariate analysis. The capacity of the model to predict MODY3 diagnosis was assessed by the area under the receiver-operating characteristic curve and was further validated in an independent sample of 851 patients (165 MODY3 and 686 non-MODY3). RESULTS In the MODY3 patients, diabetes was revealed by clinical symptoms in 25% of the cases and was diagnosed by screening in the others. Age at diagnosis of diabetes was more than 25 yr in 40% of the MODY3 patients. There was considerable variability and overlap of all assessed parameters in MODY3 and non-MODY3 patients. The best predictive model was based on criteria available at diagnosis of diabetes, including age, body mass index, number of affected generations, presence of diabetes symptoms, and geographical origin. The area under the curve of the receiver-operating characteristic analysis was 0.81. When sensitivity was set to 90%, specificity was 49%. CONCLUSIONS Differential diagnosis between MODY3 and early-onset type 2 diabetes remains difficult. Whether the proposed model will improve the pick-up rate of MODY3 diagnosis needs to be confirmed in independent populations.
Collapse
Affiliation(s)
- Christine Bellanné-Chantelot
- Department of Genetics, Assistance Publique-Hôpitaux de Paris, Pitié -Salpétrière Hospital, University Pierre et Marie Curie-Paris 6, 75013 Paris, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
90
|
Khalil CA, Travert F, Fetita S, Rouzet F, Porcher R, Riveline JP, Hadjadj S, Larger E, Roussel R, Vexiau P, Le Guludec D, Gautier JF, Marre M. Fetal exposure to maternal type 1 diabetes is associated with renal dysfunction at adult age. Diabetes 2010; 59:2631-6. [PMID: 20622173 PMCID: PMC3279566 DOI: 10.2337/db10-0419] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/02/2022]
Abstract
OBJECTIVE In animal studies, hyperglycemia during fetal development reduces nephron numbers. We tested whether this observation translates into renal dysfunction in humans by studying renal functional reserve in adult offspring exposed in utero to maternal type 1 diabetes. RESEARCH DESIGN AND METHODS We compared 19 nondiabetic offspring of type 1 diabetic mothers with 18 offspring of type 1 diabetic fathers (control subjects). Glomerular filtration rate ((51)Cr-EDTA clearance), effective renal plasma flow ((123)I-hippurate clearance), mean arterial pressure, and renal vascular resistances were measured at baseline and during amino acid infusion, which mobilizes renal functional reserve. RESULTS Offspring of type 1 diabetic mothers were similar to control subjects for age (median 27, range 18-41, years), sex, BMI (23.1 ± 3.7 kg/m(2)), and birth weight (3,288 ± 550 vs. 3,440 ± 489 g). During amino acid infusion, glomerular filtration rate and effective renal plasma flow increased less in offspring of type 1 diabetic mothers than in control subjects: from 103 ± 14 to 111 ± 17 ml/min (8 ± 13%) vs. from 108 ± 17 to 128 ± 23 ml/min (19 ± 7%, P = 0.009) and from 509 ± 58 to 536 ± 80 ml/min (5 ± 9%) vs. from 536 ± 114 to 620 ± 140 ml/min (16 ± 11%, P = 0.0035). Mean arterial pressure and renal vascular resistances declined less than in control subjects: 2 ± 5 vs. -2 ± 3% (P = 0.019) and 3 ± 9 vs. -14 ± 8% (P = 0.001). CONCLUSIONS Reduced functional reserve may reflect a reduced number of nephrons undergoing individual hyperfiltration. If so, offspring of type 1 diabetic mothers may be predisposed to glomerular and vascular diseases.
Collapse
Affiliation(s)
- Charbel Abi Khalil
- Diabetes Department, Groupe Hospitalier Bichat–Claude Bernard, Assistance Publique–Hôpitaux de Paris, Paris, France
- INSERM U695, University Paris-Diderot Paris, Paris, France
- Centre d'Investigation Clinique, Groupe Hospitalier Bichat–Claude Bernard, Assistance Publique–Hôpitaux de Paris, Paris, France
| | - Florence Travert
- Diabetes Department, Groupe Hospitalier Bichat–Claude Bernard, Assistance Publique–Hôpitaux de Paris, Paris, France
- INSERM U695, University Paris-Diderot Paris, Paris, France
- Centre d'Investigation Clinique, Groupe Hospitalier Bichat–Claude Bernard, Assistance Publique–Hôpitaux de Paris, Paris, France
| | - Sabrina Fetita
- Diabetes Department, Hôpital Saint-Louis, Assistance Publique–Hôpitaux de Paris, University Paris-Diderot Paris, France
- Centre d'Investigation Clinique, Hôpital Saint-Louis, Assistance Publique–Hôpitaux de Paris, Paris, France
- UMR-S INSERM 872, Centre de Recherche des Cordeliers, University Pierre et Marie Curie, Paris, France
| | - François Rouzet
- Medecine Nucléaire, Groupe Hospitalier Bichat–Claude Bernard, Assistance Publique–Hôpitaux de Paris, Paris, France
| | - Raphael Porcher
- Department of Biostatistics and Medical Computing, Saint-Louis University Hospital, Assistance Publique–Hôpitaux de Paris, University Paris-Diderot Paris, Paris, France
| | | | - Samy Hadjadj
- Diabetes Department, Centre Hospitalier Universitaire, Poitiers, France
| | - Etienne Larger
- Diabetes Department, Hôpital de l'Hôtel-Dieu, Assistance Publique–Hôpitaux de Paris, Paris, France
| | - Ronan Roussel
- Diabetes Department, Groupe Hospitalier Bichat–Claude Bernard, Assistance Publique–Hôpitaux de Paris, Paris, France
- INSERM U695, University Paris-Diderot Paris, Paris, France
- Centre d'Investigation Clinique, Groupe Hospitalier Bichat–Claude Bernard, Assistance Publique–Hôpitaux de Paris, Paris, France
| | - Patrick Vexiau
- Diabetes Department, Hôpital Saint-Louis, Assistance Publique–Hôpitaux de Paris, University Paris-Diderot Paris, France
| | - Dominique Le Guludec
- Medecine Nucléaire, Groupe Hospitalier Bichat–Claude Bernard, Assistance Publique–Hôpitaux de Paris, Paris, France
| | - Jean-François Gautier
- Diabetes Department, Hôpital Saint-Louis, Assistance Publique–Hôpitaux de Paris, University Paris-Diderot Paris, France
- Centre d'Investigation Clinique, Hôpital Saint-Louis, Assistance Publique–Hôpitaux de Paris, Paris, France
- UMR-S INSERM 872, Centre de Recherche des Cordeliers, University Pierre et Marie Curie, Paris, France
| | - Michel Marre
- Diabetes Department, Groupe Hospitalier Bichat–Claude Bernard, Assistance Publique–Hôpitaux de Paris, Paris, France
- INSERM U695, University Paris-Diderot Paris, Paris, France
- Centre d'Investigation Clinique, Groupe Hospitalier Bichat–Claude Bernard, Assistance Publique–Hôpitaux de Paris, Paris, France
- Corresponding author: Michel Marre,
| |
Collapse
|
91
|
Sobngwi E, Enoru S, Ashuntantang G, Azabji-Kenfack M, Dehayem M, Onana A, Biwole D, Kaze F, Gautier JF, Mbanya JC. Day-to-day variation of insulin requirements of patients with type 2 diabetes and end-stage renal disease undergoing maintenance hemodialysis. Diabetes Care 2010; 33:1409-12. [PMID: 20215452 PMCID: PMC2890330 DOI: 10.2337/dc09-2176] [Citation(s) in RCA: 47] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
OBJECTIVE To evaluate day-to-day variations of insulin needs in type 2 diabetic patients with end-stage renal disease (ESRD) on maintenance hemodialysis. RESEARCH DESIGN AND METHODS We developed a 24-h euglycemic clamp in patients who received an average of 2,200 calories in a standardized three-meal and two-snack regimen per day, adjusted to body size and sex. Intravenous insulin was adjusted every 30 min to achieve 5.5 +/- 1.1 mmol/l glycemia over 24 h prehemodialysis, during hemodialysis session, and 24 h posthemodialysis in 10 type 2 diabetic patients, aged 55.7 +/- 8.7 years with 11.9 +/- 4.5 years diabetes duration, undergoing maintenance hemodialysis for 2.3 +/- 2.3 years. Insulin requirements were derived from the dose of insulin administered to maintain euglycemia per period of time and day-to-day comparisons performed. RESULTS Mean capillary glycemia was 5.5 +/- 0.3 mmol/l prehemodialysis and 5.3 +/- 0.2 mmol/l posthemodialysis (P = 0.39). Pre- and posthemodialysis areas under the glucose curve were comparable. This was achieved by infusing 23.6 +/- 7.7 IU/24 h prehemodialysis vs. 19.9 +/- 4.9 IU/24 h posthemodialysis, indicating a 15.3% decrease posthemodialysis (P = 0.09). Basal insulin needs decreased from 0.4 +/- 0.1/h prehemodialysis to 0.3 +/- 0.1/h posthemodialysis (P = 0.01). Total boluses were decreased by 2.2 +/- 3.1 IU (P = 0.15). Changes in blood urea did not correlate with changes in insulin needs (r = 0.1, P = 0.79). CONCLUSIONS The present study has demonstrated a significant 25% reduction in basal insulin requirements the day after dialysis compared with the day before. No significant change in boluses was observed, and overall the reduction of total insulin requirements was -15% equivalent to -4 IU/day posthemodialysis of marginal statistical significance.
Collapse
Affiliation(s)
- Eugene Sobngwi
- Department of Internal Medicine and Specialties, Faculty of Medicine and Biomedical Sciences, University of Yaoundé 1, Yaoundé, Cameroon.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
92
|
Bourron O, Daval M, Hainault I, Hajduch E, Servant JM, Gautier JF, Ferré P, Foufelle F. Biguanides and thiazolidinediones inhibit stimulated lipolysis in human adipocytes through activation of AMP-activated protein kinase. Diabetologia 2010; 53:768-78. [PMID: 20043143 DOI: 10.1007/s00125-009-1639-6] [Citation(s) in RCA: 47] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/17/2009] [Accepted: 11/26/2009] [Indexed: 01/22/2023]
Abstract
AIMS/HYPOTHESIS In rodent adipocytes, activated AMP-activated protein kinase reduces the lipolytic rate. As the hypoglycaemic drugs metformin and thiazolidinediones activate this enzyme in rodents, we tested the hypothesis that in addition to their known actions they could have an anti-lipolytic effect in human adipocytes. METHODS Adipose tissue was obtained from individuals undergoing plastic surgery. Adipocytes were isolated and incubated with lipolytic agents (isoprenaline, atrial natriuretic peptide) and biguanides or thiazolidinediones. Lipolysis was quantified by the glycerol released in the medium. AMP-activated protein kinase activity and phosphorylation state were determined using standard procedures. RESULTS In human adipocytes, isoprenaline and atrial natriuretic peptide stimulated the lipolytic rate three- to fourfold. Biguanides and thiazolidinediones activated AMP-activated protein kinase and inhibited lipolysis by 30-40%, at least in part by inhibiting hormone-sensitive lipase translocation to the lipid droplet. Inhibition of AMP-activated protein kinase by compound C precluded this inhibitory effect on lipolysis. Stimulation of lipolysis also induced an activation of AMP-activated protein kinase concomitant with a drop in ATP concentration. CONCLUSIONS/INTERPRETATION We show for the first time in human adipocytes that biguanides and thiazolidinediones activate AMP-activated protein kinase, thus counteracting lipolysis induced by lipolytic agents. In addition, beta-agonist- or ANP-stimulated lipolysis increases AMP-activated protein kinase activity. This is because of an increase in the AMP/ATP ratio, linked to activation of some of the released fatty acids into acyl-CoA. AMP-activated protein kinase activation could represent a physiological means of avoiding a deleterious drain of energy during lipolysis but could be used to restrain pharmacological release of fatty acids.
Collapse
Affiliation(s)
- O Bourron
- Centre de Recherche des Cordeliers, INSERM, UMR-S 872, 15 rue de l'école de médecine, Paris F-75006, France
| | | | | | | | | | | | | | | |
Collapse
|
93
|
Meur G, Simon A, Harun N, Virally M, Dechaume A, Bonnefond A, Fetita S, Tarasov AI, Guillausseau PJ, Boesgaard TW, Pedersen O, Hansen T, Polak M, Gautier JF, Froguel P, Rutter GA, Vaxillaire M. Insulin gene mutations resulting in early-onset diabetes: marked differences in clinical presentation, metabolic status, and pathogenic effect through endoplasmic reticulum retention. Diabetes 2010; 59:653-61. [PMID: 20007936 PMCID: PMC2828668 DOI: 10.2337/db09-1091] [Citation(s) in RCA: 115] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
OBJECTIVE Heterozygous mutations in the human preproinsulin (INS) gene are a cause of nonsyndromic neonatal or early-infancy diabetes. Here, we sought to identify INS mutations associated with maturity-onset diabetes of the young (MODY) or nonautoimmune diabetes in mid-adult life, and to explore the molecular mechanisms involved. RESEARCH DESIGN AND METHODS The INS gene was sequenced in 16 French probands with unexplained MODY, 95 patients with nonautoimmune early-onset diabetes (diagnosed at <35 years) and 292 normoglycemic control subjects of French origin. Three identified insulin mutants were generated by site-directed mutagenesis of cDNA encoding a preproinsulin-green fluorescent protein (GFP) (C-peptide) chimera. Intracellular targeting was assessed in clonal beta-cells by immunocytochemistry and proinsulin secretion, by radioimmunoassay. Spliced XBP1 and C/EBP homologous protein were quantitated by real-time PCR. RESULTS A novel coding mutation, L30M, potentially affecting insulin multimerization, was identified in five diabetic individuals (diabetes onset 17-36 years) in a single family. L30M preproinsulin-GFP fluorescence largely associated with the endoplasmic reticulum (ER) in MIN6 beta-cells, and ER exit was inhibited by approximately 50%. Two additional mutants, R55C (at the B/C junction) and R6H (in the signal peptide), were normally targeted to secretory granules, but nonetheless caused substantial ER stress. CONCLUSIONS We describe three INS mutations cosegregating with early-onset diabetes whose clinical presentation is compatible with MODY. These led to the production of (pre)proinsulin molecules with markedly different trafficking properties and effects on ER stress, demonstrating a range of molecular defects in the beta-cell.
Collapse
Affiliation(s)
- Gargi Meur
- Section of Cell Biology, Division of Medicine, Imperial College London, London, U.K
| | - Albane Simon
- Universite Paris Descartes, INSERM U845, Pediatric Endocrinology, Hopital Necker Enfants Malades Paris, Paris, France
| | - Nasret Harun
- Section of Cell Biology, Division of Medicine, Imperial College London, London, U.K
| | - Marie Virally
- Department of Endocrinology and Diabetes, Lariboisière Hospital, University Paris-Diderot Paris-7, Paris, France
| | - Aurélie Dechaume
- Centre National de la Recherche Scientifique-UMR8090, Lille Institute of Biology, Lille 2 University, Pasteur Institute, Lille, France
| | - Amélie Bonnefond
- Centre National de la Recherche Scientifique-UMR8090, Lille Institute of Biology, Lille 2 University, Pasteur Institute, Lille, France
| | - Sabrina Fetita
- Department of Endocrinology and Diabetes, Clinical Investigation Center CIC9504, Saint-Louis Hospital, INSERM, U872, University Paris-Diderot Paris-7, Paris, France
| | - Andrei I. Tarasov
- Section of Cell Biology, Division of Medicine, Imperial College London, London, U.K
| | - Pierre-Jean Guillausseau
- Department of Endocrinology and Diabetes, Lariboisière Hospital, University Paris-Diderot Paris-7, Paris, France
| | | | - Oluf Pedersen
- Hagedorn Research Institute and Steno Diabetes Center, Gentofte, Denmark
- Faculty of Health Science, University of Aarhus, Aarhus, Denmark
- Institute of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - Torben Hansen
- Hagedorn Research Institute and Steno Diabetes Center, Gentofte, Denmark
- Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark
| | - Michel Polak
- Universite Paris Descartes, INSERM U845, Pediatric Endocrinology, Hopital Necker Enfants Malades Paris, Paris, France
| | - Jean-François Gautier
- Department of Endocrinology and Diabetes, Clinical Investigation Center CIC9504, Saint-Louis Hospital, INSERM, U872, University Paris-Diderot Paris-7, Paris, France
| | - Philippe Froguel
- Centre National de la Recherche Scientifique-UMR8090, Lille Institute of Biology, Lille 2 University, Pasteur Institute, Lille, France
- Genomic Medicine, Hammersmith Hospital, Imperial College, London, U.K
| | - Guy A. Rutter
- Section of Cell Biology, Division of Medicine, Imperial College London, London, U.K
- Corresponding authors: Guy A. Rutter, , or Philippe Froguel,
| | - Martine Vaxillaire
- Centre National de la Recherche Scientifique-UMR8090, Lille Institute of Biology, Lille 2 University, Pasteur Institute, Lille, France
| |
Collapse
|
94
|
Blouin CM, Le Lay S, Eberl A, Köfeler HC, Guerrera IC, Klein C, Le Liepvre X, Lasnier F, Bourron O, Gautier JF, Ferré P, Hajduch E, Dugail I. Lipid droplet analysis in caveolin-deficient adipocytes: alterations in surface phospholipid composition and maturation defects. J Lipid Res 2009; 51:945-56. [PMID: 19965594 PMCID: PMC2853462 DOI: 10.1194/jlr.m001016] [Citation(s) in RCA: 83] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
Caveolins form plasmalemnal invaginated caveolae. They also locate around intracellular lipid droplets but their role in this location remains unclear. By studying primary adipocytes that highly express caveolin-1, we characterized the impact of caveolin-1 deficiency on lipid droplet proteome and lipidome. We identified several missing proteins on the lipid droplet surface of caveolin-deficient adipocytes and showed that the caveolin-1 lipid droplet pool is organized as multi-protein complexes containing cavin-1, with similar dynamics as those found in caveolae. On the lipid side, caveolin deficiency did not qualitatively alter neutral lipids in lipid droplet, but significantly reduced the relative abundance of surface phospholipid species: phosphatidylserine and lysophospholipids. Caveolin-deficient adipocytes can form only small lipid droplets, suggesting that the caveolin-lipid droplet pool might be involved in lipid droplet size regulation. Accordingly, we show that caveolin-1 concentration on adipocyte lipid droplets positively correlated with lipid droplet size in obese rodent models and human adipocytes. Moreover, rescue experiments by caveolin- green fluorescent protein in caveolin-deficient cells exposed to fatty acid overload demonstrated that caveolin-coated lipid droplets were able to grow larger than caveolin-devoid lipid droplets. Altogether, these data demonstrate that the lipid droplet-caveolin pool impacts on phospholipid and protein surface composition of lipid droplets and suggest a functional role on lipid droplet expandability.
Collapse
Affiliation(s)
- Cédric M Blouin
- Centre de Recherche des Cordeliers, INSERM, U872, Université Pierre et Marie Curie - Paris 6, France
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
95
|
Choukem SP, Sobngwi E, Fetita LS, Boudou P, De Kerviler E, Boirie Y, Hainault I, Vexiau P, Mauvais-Jarvis F, Calvo F, Gautier JF. Multitissue insulin resistance despite near-normoglycemic remission in Africans with ketosis-prone diabetes. Diabetes Care 2008; 31:2332-7. [PMID: 18809633 PMCID: PMC2584191 DOI: 10.2337/dc08-0914] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
OBJECTIVE To characterize insulin action in Africans with ketosis-prone diabetes (KPD) during remission. RESEARCH DESIGN AND METHODS At Saint-Louis Hospital, Paris, France, 15 African patients with KPD with an average 10.5-month insulin-free near-normoglycemic remission period (mean A1C 6.2%) were compared with 17 control subjects matched for age, sex, BMI, and geographical origin. Insulin stimulation of glucose disposal, and insulin suppression of endogenous glucose production (EGP) and nonesterified fatty acids (NEFAs), was studied using a 200-min two-step (10 mU x m(-2) body surface x min(-1) and 80 mU x m(-2) x min (-1) insulin infusion rates) euglycemic clamp with [6,6-(2)H(2)]glucose as the tracer. Early-phase insulin secretion was determined during an oral glucose tolerance test. RESULTS The total glucose disposal was reduced in patients compared with control subjects (7.5 +/- 0.8 [mean +/- SE] vs. 10.5 +/- 0.9 mg x kg(-1) x min(-1); P = 0.018). EGP rate was higher in patients than control subjects at baseline (4.0 +/- 0.3 vs. 3.0 +/- 0.1 mg x kg(-1) x min(-1); P = 0.001) and after 200-min insulin infusion (10 mU x m(-2) x min(-1): 1.6 +/- 0.2 vs. 0.6 +/- 0.1, P = 0.004; 80 mU x m(-2) x min(-1): 0.3 +/- 0.1 vs. 0 mg x kg(-1) x min(-1), P = 0.007). Basal plasma NEFA concentrations were also higher in patients (1,936.7 +/- 161.4 vs. 1,230.0 +/- 174.1 micromol/l; P = 0.002) and remained higher after 100-min 10 mU x m(-2) x min(-1) insulin infusion (706.6 +/- 96.5 vs. 381.6 +/- 55.9 micromol/l; P = 0.015). CONCLUSIONS The triad hepatic, adipose tissue, and skeletal muscle insulin resistance is observed in patients with KPD during near-normoglycemic remission, suggesting that KPD is a form of type 2 diabetes.
Collapse
Affiliation(s)
- Simeon-Pierre Choukem
- Department of Diabetes and Endocrinology, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, University Paris-Diderot Paris 7, Paris, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
96
|
Gautier JF. [Ketosis-prone type 2 diabetes mellitus in sub-Saharan Africans: possible contribution of human herpes virus 8 infection]. Med Sci (Paris) 2008; 24:665-6. [PMID: 18601887 DOI: 10.1051/medsci/20082467665] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
97
|
Sobngwi E, Choukem SP, Agbalika F, Blondeau B, Fetita LS, Lebbe C, Thiam D, Cattan P, Larghero J, Foufelle F, Ferre P, Vexiau P, Calvo F, Gautier JF. Ketosis-prone type 2 diabetes mellitus and human herpesvirus 8 infection in sub-saharan africans. JAMA 2008; 299:2770-6. [PMID: 18560004 DOI: 10.1001/jama.299.23.2770] [Citation(s) in RCA: 82] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
CONTEXT An atypical form of type 2 diabetes mellitus (DM-2) is revealed by ketosis (ketosis-prone type 2 diabetes mellitus), frequently occurring in individuals who are black and of African origin, and characterized by an acute onset requiring transient insulin therapy. Its sudden onset suggests precipitating factors. OBJECTIVE To investigate the putative role of human herpesvirus 8 (HHV-8) in the pathogenesis of ketosis-prone DM-2. DESIGN, SETTING, AND PARTICIPANTS A cross-sectional study in which antibodies were searched against latent and lytic HHV-8 antigens using immunofluorescence. The presence of HHV-8 in genomic DNA was investigated in 22 of the participants at clinical onset of diabetes. We also tested whether HHV-8 was able to infect human pancreatic beta cells in culture in vitro. The study was conducted at Saint-Louis University Hospital, Paris, France, from January 2004 to July 2005. All participants were black and of African origin: 187 were consecutive diabetic patients of whom 81 had ketosis-prone DM-2 and 106 had nonketotic DM-2, and 90 individuals were nondiabetic control participants who were matched for age and sex. MAIN OUTCOME MEASURES Seroprevalence of HHV-8 and percentage of patients with HHV-8 viremia at onset in ketosis-prone DM-2. RESULTS HHV-8 antibodies were found in 71 patients (87.7%) with ketosis-prone DM-2 vs 16 patients (15.1%) with nonketotic DM-2 (odds ratio, 39.9; 95% confidence interval, 17.1-93.4; P < .001) and 36 of the control participants (40.0%) (odds ratio, 10.7; 95% confidence interval, 4.9-23.4; P < .001). HHV-8 in genomic DNA was present in 6 of 13 patients with ketosis-prone DM-2 tested at acute onset and in 0 of 9 patients with nonketotic DM-2. HHV-8 proteins were present in human islet cells that were cultured for 4 days in the presence of HHV-8. CONCLUSIONS In this preliminary cross-sectional study, the presence of HHV-8 antibodies was associated with ketosis-prone DM-2 in patients of sub-Saharan African origin. Longitudinal studies are required to understand the clinical significance of these findings.
Collapse
Affiliation(s)
- Eugène Sobngwi
- Department of Endocrinology and Diabetes, Saint-Louis University Hospital, 1 Avenue Claude Vellefaux, 75475 Paris Cedex 10, France
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
98
|
Gautier JF, Choukem SP. Les incrétines. NUTR CLIN METAB 2008. [DOI: 10.1016/j.nupar.2008.04.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
99
|
Tarasov AI, Nicolson TJ, Riveline JP, Taneja TK, Baldwin SA, Baldwin JM, Charpentier G, Gautier JF, Froguel P, Vaxillaire M, Rutter GA. A rare mutation in ABCC8/SUR1 leading to altered ATP-sensitive K+ channel activity and beta-cell glucose sensing is associated with type 2 diabetes in adults. Diabetes 2008; 57:1595-604. [PMID: 18346985 PMCID: PMC6101196 DOI: 10.2337/db07-1547] [Citation(s) in RCA: 54] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
OBJECTIVE ATP-sensitive K(+) channels (K(ATP) channels) link glucose metabolism to the electrical activity of the pancreatic beta-cell to regulate insulin secretion. Mutations in either the Kir6.2 or sulfonylurea receptor (SUR) 1 subunit of the channel have previously been shown to cause neonatal diabetes. We describe here an activating mutation in the ABCC8 gene, encoding SUR1, that is associated with the development of type 2 diabetes only in adults. RESEARCH DESIGN AND METHODS Recombinant K(ATP) channel subunits were expressed using pIRES2-based vectors in human embryonic kidney (HEK) 293 or INS1(832/13) cells and the subcellular distribution of c-myc-tagged SUR1 channels analyzed by confocal microscopy. K(ATP) channel activity was measured in inside-out patches and plasma membrane potential in perforated whole-cell patches. Cytoplasmic [Ca(2+)] was imaged using Fura-Red. RESULTS A mutation in ABCC8/SUR1, leading to a Y356C substitution in the seventh membrane-spanning alpha-helix, was observed in a patient diagnosed with hyperglycemia at age 39 years and in two adult offspring with impaired insulin secretion. Single K(ATP) channels incorporating SUR1-Y356C displayed lower sensitivity to MgATP (IC(50) = 24 and 95 micromol/l for wild-type and mutant channels, respectively). Similar effects were observed in the absence of Mg(2+), suggesting an allosteric effect via associated Kir6.2 subunits. Overexpression of SUR1-Y356C in INS1(832/13) cells impaired glucose-induced cell depolarization and increased in intracellular free Ca(2+) concentration, albeit more weakly than neonatal diabetes-associated SUR1 mutants. CONCLUSIONS An ABCC8/SUR1 mutation with relatively minor effects on K(ATP) channel activity and beta-cell glucose sensing causes diabetes in adulthood. These data suggest a close correlation between altered SUR1 properties and clinical phenotype.
Collapse
Affiliation(s)
- Andrei I Tarasov
- Section of Cell Biology, Division of Medicine, Imperial College London, London, UK
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
100
|
Bellanné-Chantelot C, Carette C, Riveline JP, Valéro R, Gautier JF, Larger E, Reznik Y, Ducluzeau PH, Sola A, Hartemann-Heurtier A, Lecomte P, Chaillous L, Laloi-Michelin M, Wilhem JM, Cuny P, Duron F, Guerci B, Jeandidier N, Mosnier-Pudar H, Assayag M, Dubois-Laforgue D, Velho G, Timsit J. The type and the position of HNF1A mutation modulate age at diagnosis of diabetes in patients with maturity-onset diabetes of the young (MODY)-3. Diabetes 2008; 57:503-8. [PMID: 18003757 DOI: 10.2337/db07-0859] [Citation(s) in RCA: 143] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
OBJECTIVE The clinical expression of maturity-onset diabetes of the young (MODY)-3 is highly variable. This may be due to environmental and/or genetic factors, including molecular characteristics of the hepatocyte nuclear factor 1-alpha (HNF1A) gene mutation. RESEARCH DESIGN AND METHODS We analyzed the mutations identified in 356 unrelated MODY3 patients, including 118 novel mutations, and searched for correlations between the genotype and age at diagnosis of diabetes. RESULTS Missense mutations prevailed in the dimerization and DNA-binding domains (74%), while truncating mutations were predominant in the transactivation domain (62%). The majority (83%) of the mutations were located in exons 1- 6, thus affecting the three HNF1A isoforms. Age at diagnosis of diabetes was lower in patients with truncating mutations than in those with missense mutations (18 vs. 22 years, P = 0.005). Missense mutations affecting the dimerization/DNA-binding domains were associated with a lower age at diagnosis than those affecting the transactivation domain (20 vs. 30 years, P = 10(-4)). Patients with missense mutations affecting the three isoforms were younger at diagnosis than those with missense mutations involving one or two isoforms (P = 0.03). CONCLUSIONS These data show that part of the variability of the clinical expression in MODY3 patients may be explained by the type and the location of HNF1A mutations. These findings should be considered in studies for the search of additional modifier genetic factors.
Collapse
Affiliation(s)
- Christine Bellanné-Chantelot
- Département de Génétique, Groupe Hospitalier Pitié-Salpétrière, Bât 6 rue Lapeyronie, 47/83 Boulevard de l'Hôpital, 75651 Paris Cedex 13, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|